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SUMMARY 
Genetic code expansion is a central goal of protein research and engineering with a 
broad range of applications. The ability to reliably incorporate non-canonical amino acids 
(ncAAs) in a site-specific manner has expanded the protein engineering toolbox to enable 
the functionalization of proteins with affinity, spectroscopic, and chemically functional 
components.1 Consequently, incorporation of functional ncAAs has enabled bio-
orthogonal modification of proteins, a powerful and emerging tool critical to the 
development of both fundamental protein science and applied biotechnologies.2 The most 
common technique for the translation of proteins incorporating site-specific ncAA 
mutations is amber codon suppression.3 This technique leverages an orthogonal translation 
system (OTS) consisting of a dedicated aminoacyl-tRNA synthetase (aaRS):tRNA pair 
mediating the translation of a protein with a specific ncAA at the target position encoded 
by a repurposed amber codon.4 Typically, ncAA co-translation in Escherichia coli is 
mediated by an OTS developed from an engineered bio-orthogonal tyrosyl-tRNA 
synthetase:tRNA pair from Methanococcus jannaschii.1 However, despite the potential 
promised by an expanded genetic code, the routine application of the OTS strategy is 
consistently hindered by considerable and recurring barriers.5 
These persistent challenges include cross-reactive OTSs, incompatibility with 
endogenous elongation factors, and discrimination by additional translation components. 
These factors affect both the yield and purity of co-translated ncAA proteins as well as the 
fitness and viability of the host microorganism.6-10 Furthermore, the diversity of these 
modifications is reduced to a specific set of ncAAs compatible with existing and 
 xix 
engineered translation machinery, thereby significantly reducing the readily available 
scope of potential chemistries and applications. Consequently, current efforts are 
commonly limited to single-site incorporation with a reduced set of ncAAs.11 These 
challenges highlight a pressing need to pursue improved engineering strategies beyond 
OTS development that will enable translation of increasingly complex peptide products, 
with multi-site incorporation and multiple ncAA incorporation.12, 13 
One obstacle limiting expansion of the genetic code is elongation factor Tu (EF-
Tu), a guanosine triphosphatase (GTPase). EF-Tu serves two functions in translation. 
While most commonly recognized for translocation of aa-tRNAs to the ribosome, it also 
plays a critical role in quality control.14 All twenty aa-tRNAs associate with EF-Tu having 
carefully tuned interactions that prevent misacylated tRNAs from being delivered to the 
ribosome for translation. Similar to misacylated tRNAs, ncaa-tRNAs are non-native 
substrates and can be discriminated by EF-Tu thus preventing their incorporation into the 
translated protein. Past efforts have typically circumvented EF-Tu’s editing mechanism by 
targeting ncAAs that are tolerated as substrates. For particularly intractable ncAAs, 
orthogonal EF-Tus have been developed or tRNAs have been engineered to optimize their 
binding with EF-Tu.15 However, these efforts fail to recognize EF-Tu’s comprehensive 
effect on translation.11 As a result, engineering EF-Tu to accept an expanded set of ncaa-
tRNA substrates represents a unique opportunity for expanding ncAA incorporation.11, 15-
18  
We hypothesize that EF-Tu's rejection of ncaa-tRNAs is a significant limiting 
factor in the translation of ncAAs. Using both in vitro and in vivo assays, we have evaluated 
tRNA and EF-Tu variants’ ability to efficiently translate ncAAs, specifically valine analogs 
 xx 
(in vitro) and phosphoserine (in vivo). Broadly, the research presented herein works toward 
characterizing the tRNA and EF-Tu mutations required to overcome a limiting step in the 
translation of ncAAs and promote more efficient delivery of ncAA-tRNAs to the ribosome. 
In contrast to typical efforts, we demonstrate the advantages of using computational 
analysis to broaden EF-Tu’s substrate specificity. By improving host organism fitness and 
potentially allowing researchers to circumvent the question of ncAA compatibility with 
EF-Tu, this approach directly complements current research demonstrating the importance 




CHAPTER 1. INTRODUCTION 
 Abstract 
In recent years, ncAAs have established their importance in a wide range of fields 
from pharmaceuticals to polymer science. NcAAs can add any number of chemical groups 
to proteins for expanded and enhanced functionality, yet despite the importance of ncAAs 
in research, scientists’ ability to utilize these unique building blocks has been limited by 
their ability to incorporate them efficiently into proteins. To address this challenge, 
researchers have examined how the canonical twenty amino acids are incorporated, 
regulated, and modified in nature. This chapter focuses on achievements and techniques 
used to engineer the ribosomal translation machinery including introducing orthogonal 
translation components, directed evolution, and computationally-derived ancestral protein 
sequences.  
 Introduction  
The cellular translation machinery has evolved to translate a specific set of twenty 
amino acids. Despite the limited variety of chemical functional groups offered by the 
canonical amino acids, all organisms utilize the same set of twenty to build proteins for a 
tremendous variety of cellular applications. One might question how the wide variety of 
chemical functionality required of proteins in vivo is even possible when working with 
such a restricted set of building blocks. Nature has addressed this challenge by expanding 
the chemical complexity of protein chemistry through extensive use of post-translational 
modifications and cofactors, but these cellular techniques can be difficult to harness in the 
 2 
laboratory. One method for researchers to expand or manipulate protein chemistry is to 
directly incorporate chemical functionality during translation using ncAAs, meaning amino 
acids other than the canonical twenty. However, ncAAs are frequently rejected by the 
translation machinery and suffer from low translation rates. Other challenges include 
incorporation of an ncAA at multiple positions in the same protein or translating several 
different ncAAs into a single protein. However, despite the challenges associated with 
using ncAAs, many scientific fields are actively benefiting from their application. 
 
Figure 1.1 Applications of ncAAs. A web diagram illustrating research areas that 
employ ncAAs. 
NcAAs offer a wide variety of chemical functionalities that researchers can exploit 
for any number of uses such as chemical tags, enhanced or altered functionality, increased 
stability, or post-translational modifications (Figure 1.1). For example, biotherapeutics 
depend on ncAAs to address a variety of challenges including low permeability across 
biological barriers and rapid degradation in vivo.19, 20 NcAAs are also used to chemically 
tag proteins at a specific location without labeling non-target amino acids or proteins. Such 
tagged proteins have application in a range of fields including in vivo cell imaging, 
proteomics, and drug-delivery systems.21-24 Translation of ncAAs is also used in basic 
protein research to directly incorporate post-translational modifications during translation, 
thereby offering reliable protein modification while avoiding the challenges associated 
with post-translational enzymatic or chemical methods.17, 25 Even nanoscience and polymer 
 3 
science are exploring the expanded possibilities ncAAs offer.26 Due to their many 
applications, researchers have sought methods to insert ncAAs into peptides and proteins.   
 
Figure 1.2 Techniques summary. This flow chart shows methods used to incorporate 
ncAAs into peptides and proteins. This chapter focuses on methods highlighted 
under “ribosome-mediated synthesis” wherein the ribosome translation machinery 
is engineered to promote efficient translation of ncAAs.  
A number of techniques exist to facilitate ncAA incorporation into proteins and 
peptides, including synthetic methods such as solid-phase synthesis, in vitro systems, and 
biological methods.27-29 Biological approaches to incorporating ncAAs are split into non-
ribosomal protein synthesis and ribosome-mediate translation. Herein we will focus on the 
latter (Figure 1.2).30 In nature, ribosome-mediated translation requires many cellular 
components including the ribosome, transfer-RNAs (tRNAs), aminoacyl-tRNA 
synthetases, and elongation factors which synthesize proteins in vivo (Figure 1.3). 
Engineering the ribosome translation machinery to translate ncAAs has required 
overcoming number of biological proofreading steps that reject ncAAs during translation. 
Researchers have addressed these challenges using a variety of techniques including 
developing orthogonal translation components, directed evolution of translation factors, 
and ancestral sequence reconstruction.  
 Engineering translation machinery  
 4 
 
Figure 1.3 Cartoon of translation machinery. Ribosome (lavender), EF-Tu (aqua), 
synthetases (green), tRNA (black), amino acids (circles) and ncAA (stars) are 
represented. 
Cellular translation utilizes a number of proofreading steps during which it can 
identify and reject ncAAs, refusing to translate them into a protein. Specific steps in 
translation allow the ribosome, tRNAs, synthetases, and elongation factor Tu (EF-Tu) to 
ensure accurate translation of the canonical amino acids and exclusion of any unnatural 
ones. In the first proofreading step, the synthetase acylates the corresponding tRNA with 
its correct amino acid. Next, the EF-Tu double checks the aminoacyl-tRNA is charged with 
the correct amino acid and delivers the complex to the ribosome for translation. Finally, 
the ribosome may fail accommodate the ncAA and may refuse to incorporate it into a 
protein. Each of these three steps is a point at which an ncAA may be rejected by the 
translation machinery. Researchers are working to address each of these proofreading steps 
in translation.  
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Figure 1.4 EF-Tu crystal structure (gray) complexed with tRNAPhe (purple) and 
the amino acid target (orange). 
Due to research performed in this area, the ribosome is known to be relatively 
promiscuous and can often accommodate ncAAs; however synthetases, tRNAs, and EF-
Tus often contribute to low rates of ncAA incorporation.17, 31, 32 Researchers have 
developed methods to engineer these components of the translation machinery. Their 
techniques include using orthogonal translation components, directed evolution of 
proteins, and ancestral proteins.  
Great strides have been made by researchers to address tRNAs’ and synthetases’ 
exclusion of ncAAs. Synthetases and tRNAs work in cellular translation as an orthogonal 
pair, specific for an amino acid be it canonical or unnatural. To incorporate an ncAA, a 
new, orthogonal tRNA and synthetase are required.3, 33 This means that although the tRNA 
and synthetase must recognize each other, it is critical they do not interact with any other 
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tRNAs or synthetases in the cell since these pairs are already assigned to a specific amino 
acid. Rather than develop tRNAs or synthetases de novo, a common approach is to adopt a 
tRNA/synthetase pair from another domain of life. Since tRNAs and synthetases are often 
domain or even species specific, a pair from another domain will likely be orthogonal to 
all other tRNA:synthetase pairs in an organism’s translation machinery.  
 
Figure 1.5 SelB crystal structure (gray) complexed with tRNASec (purple). 
Once an orthogonal pair has been identified, it is engineered specifically for the 
ncAA of choice. To begin, the tRNA anticodon loop must be altered to a codon that will 
be exclusively assigned to the ncAA, often the amber stop codon. Additionally, the 
synthetase must be engineered to exclusively recognize the corresponding tRNA and ncAA 
of choice.1 While this method has been used to successfully translate many ncAAs, it is not 
sufficient for all ncAAs. Even with the addition of an effectively engineered tRNA and 
synthetase, EF-Tu’s proofreading capabilities can still prevent ncAA translation (Figure 
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1.4).7, 34 In such cases, the orthogonal tRNA/synthetase pair method must be supplemented 
by the addition of an EF-Tu which will accommodate the ncAA.16, 17  
An example in nature of an elongation factor exclusive for one amino acid is SelB 
(Figure 1.5). In vivo, SelB, a paralog of EF-Tu, is specific for the twenty-first amino acid, 
selenocysteine.35 EF-Tu does not participate in the translation of selenocysteine. Rather, 
organisms that can directly translate selenocysteine using the ribosomal translation 
machinery do so using SelB as an elongation factor exclusive for the delivery of 
selenocysteinyl-tRNA to the ribosome.  
Similarly, EF-Tu must be engineered by researchers to allow certain ncAAs to be 
efficiently incorporated by the translation machinery. Phosphoserine (Sep) is an example 
of an ncAA that required an exclusive EF-Tu.17 An EF-Tu specifically engineered to 
accommodate the desired ncAA can be used in conjunction with an orthogonal 
tRNA/synthetase pair, creating an orthogonal triplet specific for the ncAA. Translation of 
Sep requires an orthogonal triplet, tRNA, synthetase, and EF-Tu, in order to be efficiently 
translated in an in vivo system. To engineer EF-Tu for Sep, random mutagenesis was used 
to alter the amino acid binding pocket of EF-Tu. An in vivo selection process was then used 
to identify an EF-Tu able to specifically recognize and accommodate Sep. However, this 
method would require a novel, engineered EF-Tu for each ncAA. Instead, directed 
evolution has been expanded by incorporating evolutionary information into protein library 
design.  
In the case of EF-Tu, one plan of attack would be to engineer an orthogonal EF-Tu 
for each ncAA; however, an alternative would be to employ evolutionary data to develop 
more promiscuous EF-Tus. These EF-Tus would be able to recognize a broader range of 
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substrates, in this case, a broader range of amino acids, specifically ncAAs. Higher-order 
directed evolution methods which use ancient evolutionary information have been used to 
engineer proteins with increased promiscuity. 
 Ancestral sequence reconstruction  
In addition to orthogonal translation components and directed evolution of proteins, 
fresh approaches that exploit ancient evolutionary information are proving their utility in 
protein engineering. Instead of using an exhaustive or random search for mutations that 
impart novel functionality, researchers can use ancestral sequence information to mine 
sequence space that has already been tested for viability by nature. These higher-order 
directed evolution strategies, such as ancestral sequence reconstruction (ASR), can be used 
to direct protein engineering to design variants with desirable phenotypes such as increased 
stability or promiscuity. These traits, especially increased promiscuity, may be useful to 
engineer translation machinery which is better able to accommodate ncAAs.  
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Figure 1.6 Phylogenetic tree showing increased Km and Vmax for ancestor A. This 
example of a protein phylogeny illustrates an improved Km and Vmax for ancestral 
proteins over modern proteins. All graphs show the rate of reaction versus substrate 
concentration. Modern proteins from species F and D show low Km and Vmax. The 
ancestral protein inferred at node A shows an increase Km and Vmax. 
ASR is a computational technique that can rewind the tape of evolution and 
resurrect ancient proteins that theoretically once existed. This method uses extant protein 
sequences to computationally determine protein sequences that existed at various 
speciation events.36 The advantage of this technique is that these ancestral proteins have 
already been tested by nature and deemed fit to survive. In several labs, ASR has been 
successfully used to identify protein sequences with increased thermostability, 
promiscuous enzymatic activity, or greater stability during directed evolution.37-39 
One way ASR has facilitated protein engineering is by directing the design of more 
staple protein variants. For example, ancestral proteins can have increased thermostability 
and kinetic stability which is thought to be derived from living on a hotter planet during 
the Precambrian period.37, 38 Over billions of years, proteins evolved in conditions that were 
slowly becoming more moderate in terms of temperature, leading to modern proteins which 
are often stable only within a very narrow temperature range (Figure 1.6).  
Additionally, ASR has produced ancestral proteins that demonstrate greater 
substrate promiscuity. Resurrected β-lactamases from the Precambrian period were found 
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not only to have resistance to penicillin antibiotics, but they also demonstrated activity 
against third-generation antibiotics. In contrast, modern β-lactamases have more limited 
enzymatic capabilities and are not effective against third generation antibiotics.38 Since 
promiscuous function in enzymes is thought to be advantageous when seeking to evolve 
novel protein function, ancestral proteins may be better scaffolds to use in directed 
evolution protein engineering.40  
Another technique combines directed evolution and ASR by introducing 
stabilizing, ancestral mutations into an evolving protein thereby compensating for the 
destabilizing mutations which seek novel function. Mutations which lead to promiscuous 
or novel function are generally destabilizing and often reduce or eliminate enzymatic 
activity. By bringing a protein sequence closer to the ancestral sequence, the protein can 
better mitigate the effects of destabilizing mutations that arise during directed evolution.39 
This ancestral-modern hybrid can serve as a better scaffold on which to introduce mutations 
during directed evolution. A more stable protein can accumulate a wider range of mutations 
thereby allowing a broader search of sequence space, the better to seek novel enzymatic 
function.  
The increased promiscuity of ancestral proteins suggests ancestral protein libraries 
present profitable sequence space to mine for the ability to translate ncAAs. Although the 
modern translation machinery has evolved high specificity for only twenty amino acids, 
ancient translation components may be more promiscuous and may accept a wider range 
of substrates possibly including ncAAs. Additionally, these ancient sequences can direct 
stabilizing mutations in engineered proteins which may compensate for destabilizing 
mutations while seeking novel function via directed evolution.  
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Methods to incorporate ncAAs continue to evolve as researchers’ understanding of 
protein synthesis continues to develop. Initially the tRNA and synthetase were targeted; 
researchers knew an orthogonal pair was required for each amino acid regardless of 
whether that amino acid was natural or unnatural. The concept of adding orthogonal 
translation components was expanded to include engineered EF-Tus, developed using 
directed evolution. Currently, higher-order directed evolution offers researchers ancestral 
protein sequences as a new way to approach ncAA translation. Ancestral sequences can 
offer both increased stability and promiscuity thereby acting upon a wider range of 
substrates than modern protein sequences. Stabilizing, ancestral mutations can also 
compensate for destabilizing mutations, a vital component when seeking altered or novel 
function via directed evolution. Ultimately, the way directed evolution impacts ncAA 
translation will continue to develop as scientists’ understanding of both translation and 
evolution improves.  
 Approach 
These advanced protein engineering strategies present the opportunity to alter EF-
Tu's substrate specificity. Within the framework of this strategy, there are two approaches 
to broaden EF-Tu’s substrate acceptance. One is to knockout EF-Tu’s proofreading 
capabilities to develop a variant that can accommodate additional ncAAs. This method, 
however, requires a trade-off between the degree of polyspecificity desired to translate 
ncAAs and the specificity required for host organism survival. Herein, we present an 
alternative strategy: engineering a novel EF-Tu with broader ncAA compatibilities to be 
used in complement with native EF-Tu. This strategy parallels an evolved mechanism for 
cellular co-translational incorporation of selenocysteine (Sec) which uses a dedicated 
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elongation factor, SelB, in concert with EF-Tu. This precedent employing SelB supports 
our approach to engineer a substrate-promiscuous EF-Tu that can work in parallel with 
native elongation factors.  
Computational methods that exploit models of molecular evolution have been 
previously employed to develop enzymes with expanded substrate scope. These strategies 
are based on the concept that enzymes evolved specialized activity from generic activities, 
a theory that is supported by research demonstrating ancestral proteins exhibit broader 
substrate compatibility than their modern counterparts.38, 40 To develop polyspecific EF-
Tu variants, we employed multiple computational methods predicated on the assumption 
that ancestral EF-Tu might have demonstrated expanded substrate scope. One method, 
ancestral sequence reconstruction (ASR), infers ancestral protein sequences based on 
theories of evolution. This library was developed by Dr. Eric Gaucher.37 We also used an 
EF-Tu library developed by Dr. Megan Cole based on reconstructing evolutionary adaptive 
paths (REAP). The REAP method assumes, based on sequence similarity, that SelB and 
EF-Tu are paralogues.41 This in turn suggests EF-Tu and SelB share a common ancestor 
that exhibited broader substrate-compatibility than modern elongation factors. Given this 
reasoning, EF-Tu and SelB are suitable protein families for REAP analysis toward 
engineering a promiscuous EF-Tu. Additional library techniques include consensus 
sequences developed by Dr. Cole and a binding-site transplantation library developed by 
myself. These EF-Tu libraries were complemented by two tRNA library based on tRNAVal 
and tRNASep. These libraries were generated with the intention of enabling us to examine 
aa-tRNA:EF-Tu binding from the perspective of both the protein and the tRNA.  
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Herein, we describe our efforts to transform how EF-Tu is utilized to incorporate 
ncAAs. Leveraging computational methods, we present data on four EF-Tu libraries and 
two tRNA libraries used in both in vitro and in vivo translation. We review methods used 
for EF-Tu library development (Chapter 2), in vitro assay development and optimization 
(Chapter 3 and 4), and the in vivo assay (Chapter 5). Briefly, we touch on further directions 
taken to continue the project (Chapter 6) and reflect upon possible future directions 
(Chapter 7).  
Ultimately, the in vivo assay led to the identification of EF-Tu variants which accept 
non-native substrates. By mass spectrometry, we demonstrate two variants have expanded 
substrate acceptance. Fitness tests show a polyspecific EF-Tu is an accepted addition to the 
translation machinery and improves host organism fitness relative to an ncAA-specific 
engineered EF-Tu. These results lend credence to our choice of computational method (in 
this case REAP) and also suggest that EF-Tu and SelB may have a shared, substrate-
promiscuous ancestor. Overall, we believe this approach complements current research 
highlighting the advantages of improved OTSs and promotes a more comprehensive 
approach critical to achieving future goals.  
Portions excerpted from a review article previously published as Cox, V.E. and 
Gaucher, E.A. 2015. Molecular evolution directs protein translation using ncAAs. Curr. 
Protoc. Chem. Biol. 7:223 ‐228. doi: 10.1002/97804705592715. Copyright held 
by John Wiley & Sons, Inc. for all excerpted text and figures.  
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CHAPTER 2. EF-TU LIBRARY DESIGN: ASR, CONSENSUS, 
REAP, AND BINDING-SITE TRANSPLANTATION  
 Introduction to library design  
While several methods have been successfully used to develop ncAA-specific EF-
Tu variants, in order to design a substrate-promiscuous EF-Tu a different strategy was 
required. To explore the mutations required to permit ncAA translation, EF-Tu variants 
were developed using four methods of protein library design: consensus sequence design, 
ancestral sequence reconstruction, reconstructing evolutionary adaptive pathways, and 
binding-site transplantation.36, 41, 42 These techniques offer a variety of methods all intended 
to generate small, phenotypically-diverse libraries with high functionality. The consensus 
sequence, as well as ASR, mutate residues throughout the secondary structure of the 
protein. The REAP method identifies amino acid residues associated with altered protein 
function, and the binding-site transplantation library targets the six residues comprising the 
amino-acid binding site.  
Table 2.1 Table of computational methods used to develop EF-Tu libraries. 
Libraries are listed along the left side; library characteristics are listed across the 
top. 
 
Each of these methods has different benefits and drawbacks (Table 2.1). Consensus 
sequence construction is compatible with a low-throughput assay, but it only samples 
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extant protein sequences and can be negatively impacted by ignoring epistatic interactions. 
It also results in only a single variant; however, that variant can be a viable scaffold for 
future mutations. Conversely, ASR computationally infers ancestral sequences and can be 
used to develop a larger library. Previous work has found that ancestral sequences can have 
greater thermostability and may exhibit greater polyspecificity; however, these variants 
might not be compatible with modern translation factors (e.g. tRNAs, ribosome, and other 
elongation factors).38, 41 REAP is the only technique that samples both modern and 
ancestral sequence space. This method focuses on generating variants with diverse 
phenotypes by targeting sites of functional divergence. However, in this case REAP only 
infers possible mutation sites; it does not recommend what amino acids should be used as 
substitutions. To limit the library size, we used alanine scanning, but if using site-saturation 
or many combinations of mutations, a REAP library can become too large for low-
throughput screening techniques. The binding-site transplantation library explores the 
possibility that promiscuous amino acid binding sites may be naturally occurring in other 
species. This library replaces the six residues comprising the amino acid binding pocket in 
E. coli EF-Tu, with binding site residues from EF-Tus found in other species to examine if 
other species have more promiscuous binding pockets.  
 Consensus  
Generating a consensus sequence involves sampling homologous extant sequences 
of a protein to generate a single sequence featuring the most common amino acid at each 
position in the protein. A significant advantage of using a consensus sequence is that it can 
be highly stable and thus can make exceptionally good scaffolds on which to make further 
potentially destabilizing mutations.36 This sequence was developed by Dr. Cole. 
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 ASR  
ASR is a computational methodology used to infer ancestral proteins using extant, 
(modern) protein sequences as input. There is evidence to suggest that ancestral proteins 
can offer a number of advantages (e.g. thermostability).37 In particular, some ancestral 
proteins have been found to accept a broader range of substrates.38 Based on these data, it 
is reasonable to theorize that ancestral EF-Tu variants may bind a broader range of 
substrates, specifically ncAAs. Our computational process and library design are described 
elsewhere.37, 41 This library was developed by Dr. Gaucher.  
 REAP  
 
Figure 2.1 Overview of REAP method. A phylogeny of two homologous protein 
families is shown. An MSA is generated and sites of functional divergence are 
identified via DIVERGE software and mutated to generate protein variants. 
REAP has been previously used to guide development of enzyme libraries with 
expanded substrate-acceptance.43 In brief, this method uses inferred amino acid mutation 
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rates to predict which amino acid substitutions are most likely to impart novel protein 
activity ( 
Figure 2.1). REAP analysis is based on two complementary assumptions. First, that 
amino acids which impact function are conserved during the evolution of a protein family. 
Second, residues lacking conservation are likely not relevant to activity. REAP functions 
by ranking residues according to their degree of conservation. Amino acid sites with low 
inferred mutation rates are predicted to have a high correlation to function and thus should 
be targeted during library design. Correspondingly, sites with high mutation rates are 
predicted to minimally contribute to new protein behaviors and can be excluded from 
library design. As a result, inferred mutation rates allow for the design of a targeted library 
enriched with functional variants. A central tenet of this method is that a REAP-developed 
library can retain the functional diversity of a larger library, while minimizing the number 
of variants that will not exhibit new function. This method can lead to the design of a small, 
phenotypically-diverse protein library with a large proportion of active variants. 
Conserved amino acid sites are classified during REAP analysis as exhibiting either 
Type I or Type II functional divergence. Type I indicates an amino acid is conserved for 
only one branch of a protein phylogeny.44, 45 This indicates the residue is critical for 
function in one protein family (where it is conserved), but not the other (in which the site 
is variable). Alternatively, amino acid sites exhibiting Type II functional divergence show 
conservation in both branches of the phylogeny, but the amino acid identity differs between 
families.46 This type of divergence suggests that while the amino acid position is important 
to protein activity in both families, its role in protein behavior differs.  
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Figure 2.2 Stepwise development of the REAP-designed EF-Tu library. (A) Crystal 
structure of EF-Tu (gray) complexed with tRNAPhe (purple). Phenylalanine (orange) 
situated in amino acid binding pocket. Based on Protein Data Bank structure 1OB2. 
(B) Crystal structure of SelB (gray) complexed with tRNASec (purple). Based on 
Protein Data Bank structure 2PJP. (C) Plot shows residues identified by REAP. 
Ranking of position versus distance from target. Black diamonds denote positions 
selected for mutation. Gray circles indicate amino acid sites that were not included 
in protein library. For more detailed information, refer to table. (D) Amino acids 
identified by REAP analysis. Sites mutated to generate EF-Tu library (blue). 
Residues not selected for library (cyan). EF-Tu:tRNAPhe color scheme the same as in 
panel A. 
Dr. Cole designed the REAP library by comparing EF-Tu and SelB sequences. 
Examination of sequence similarity suggests that EF-Tu and SelB can be classified as 
functionally divergent homologues making them appropriate protein families for this 
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application. EF-Tu and SelB sequences from 19 prokaryotic families were aligned and 
evaluated to identify amino acid positions predicted to influence substrate scope. The 
aligned sequences, along with phylogenies of each protein subfamily, were entered into 
DIVERGE software for analysis via three computational models (Figure 2.3, Figure 
2.4).47 Two models, Gu99 and Gu01, identify Type I functional divergence, in each case 
employing different parameters for analysis. Sites associated with Type II functional 
divergence were identified by a third model. Residues were ranked according to their 
posterior probability (Type I) or posterior ratio (Type II). This produced a rank-ordered 
list of residues with the top members being predicted to have a greater influence on 
activity (  
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Table 2.2).  
A preliminary list of residues for mutation was produced by parsing the top-ranked 
112 residues according to their distance from the target. Distances were calculated using 
the Cγ of the binding target amino acid and the Cα of the EF-Tu residue. Residues 
exceeding 13Å were removed from the list leaving 26 predicted positions in close 
proximity to the target. Of the 26 sites, 7 residues were excluded thereby culling the final 
list to 19 residues. Residues rejected included aliphatic residues between 12-13Å since they 
were not expected to have a significant effect on substrate acceptance. Methionine residues 
were also discounted due to their integral role in protein structure.48 Lastly, although the 
Cα of Y76 was within 13Å, the Cγ of the side chain fell outside the distance cutoff 
suggesting that mutation of the residue would not impact the structure of the amino acid 




Figure 2.3 Phylogeny used for REAP analysis based on EF-Tu sequences. 
In addition to the 19 residues selected via REAP, positions N13, V227, and V274 
were also included in library design. Since protein lengths were normalized during 
computational analysis, the first 47 residues were appraised by eye and site N13 was chosen 
for exhibiting Type I functional divergence. Sites V227 and V274 were selected based on 
proximity to the target, thereby bringing the total to 22 mutation sites targeted in the REAP 
library (Figure 2.5). 
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Figure 2.4 Phylogeny used for REAP analysis based on SelB sequences. 
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Table 2.2 Top-ranked REAP-identified positions. Amino acid numbers relative to 





Figure 2.5 Multiple sequence alignment of EF-Tu and SelB substrate binding site. 
Type I (green), Type II (orange) and residues chosen for proximity (navy) are shown 
 This selection of 22 residues represents a larger targeted sequence space than 
previous efforts. However, despite scanning more residues for activity, mutations were 
combined to generate a small, targeted library. REAP variants were built on a wild type 
Escherichia coli EF-Tu backbone and each contained 4, 8, or 12 mutations (Figure 2.6). 
This approach contrasts with previous publications which have typically targeted a more 
limited number of amino acid sites, but in greater combinations (e.g., via site-saturation) 
leading to much larger libraries.11, 17 In line with prior research, the library was developed 
using alanine scanning to expand the physical space within the amino acid binding pocket.6, 
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11, 16 Since increased flexibility in the binding pocket can broaden substrate acceptance, 
glycine could have been a promising amino acid replacement instead of alanine.6, 49 
However, because each variant was designed with multiple mutations, replacing residues 
with glycine was predicted to have a detrimental effect on protein structure.  
 
Figure 2.6 Mutations made to generate REAP library. Protein variants are named 
by the number of mutations (four, eight, or twelve) followed by letters to distinguish 
among variants with four mutations. Sequence of wild type E. coli EF-Tu is shown 
for reference. 
 Binding-site library development  
The binding-site transplantation library was developed by mutating the six amino 
acid residues in EF-Tu’s amino-acid binding site. Previous research has demonstrated the 
potential to engineer an EF-Tu variant specific for a particular ncAA by mutating only 
these six residues.17 Based on this research, we hypothesize that if mutating these six 
residues can make EF-Tu more specific, different mutations in the same positions might 
render the protein polyspecific with broader substrate specificity. To test this hypothesis, 
we created a new EF-Tu variant library which reflects amino-acid binding sites found in 
EF-Tu proteins from different species.  
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Figure 2.7 Binding-site transplantation library. Left column indicates from where 
each sequence was derived. Amino acid substations in the binding site are color-
coded: positively charged (purple), negatively charged (blue), nonpolar (green), and 
polar (yellow).  
Wild type E. coli EF-Tu was the starting point for all variants. Using BLAST, we 
identified 247 unique EF-Tu sequences representing species spanning all three domains of 
life. These sequences were then aligned using Clustal Omega and the binding sites were 
compared. These binding sites served as guidance when building the library. For each 
variant, the E. coli amino-acid binding site was mutated to reflect a unique binding site 
found in a different species, the theory being that perhaps a different species has a more 
promiscuous EF-Tu capable of translating ncAAs (Figure 2.7). These variants with 
“transplanted” binding sites were then assayed and characterized. The final library 
represented nine binding sites from the domain archaea, three from eukaryotes, and three 
from bacteria including the full sequence of E. coli. These EF-Tu were assayed in vivo for 
compatibility with Sep. Since E. coli EF-Tu is known to be incompatible with Sep, it was 
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used as a negative control. The relative ability of these variants to translate a gene 
containing Sep (at an amber stop codon) was compared to the ability of EF-Sep to 




CHAPTER 3. OPTIMIZING AMINOACYLATION PROTOCOL 
AND TRANSLATION PROTOCOL FOR TRNA VARIANTS  
Herein we discuss optimization of the aminoacylation protocol and translation 
protocol specifically for work with tRNA variants. This data relates to but does not repeat 
data presented in other chapters. The in vitro translation experiments were performed with 
a translation kit that lacked tRNAs and amino acids which is different from the kit used in 
the subsequent chapter which lacked EF-Tus. Because these in vitro translation kits contain 
both cell lysate and recombinantly expressed components, we would not necessarily expect 
kits lacking tRNA and kits lacking EF-Tu to be optimized the same way.  
 Initiated protocol to use flexizymes in lab 
Flexizymes are enzymatic RNA sequences that can replace synthetases. However, 
whereas synthetases recognize their cognate amino acid, flexizymes recognize a leaving 
group attached to the amino acid.50 The flexizyme charges the amino acid to the tRNA and 
the aa-tRNAs can then be used in an in vitro translation assay. We determined amino acids 
with the appropriate leaving group would be ordered from a commercial source. We also 
ordered the primers and were able to successfully synthesize the flexizymes. However, it 
became clear the tRNA protocol was not working. The ratio of signal to noise was low with 
high variability from day to day. Without a functional tRNA assay, the flexizyme work 
was significantly less applicable to the project. As such, we suspended work on flexizymes 
to optimize the tRNA aminoacylation and the corresponding in vitro translation assay.  
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 Optimizing the aminoacylation and in vitro translation protocols for tRNA 
variants  
3.2.1 Experimental protocols  
For these experiments, we used an aminoacylation protocol followed by in vitro 
translation. In the acylation protocol, we used all twenty tRNAs but only one amino acid 
and one synthetase; thus, we could assume the product contained only one aa-tRNA. 
Aminoacylations were performed with either radiolabeled S-35 fMet or Val as the target 
amino acid. Aminoacylations using fMet could be quantified (via scintillation) before the 
acylation was carried through the translation reaction. With Val, the aminoacylation itself 
could not be measured; the acylation had to be carried through translation before we could 
generate any data. With either amino acid, in vitro translation was measured by scintillation 
using radiolabeled S-35 fMet to initiate the peptide. The goal was to assay tRNAVal variants 
with valine analogs (Figure 3.1).  
 




In vitro translation was accomplished using a custom PURE translation kit (NEB) 
from which tRNAs and amino acids had been withheld. To perform in vitro translation, we 
added the aminoacylation reaction (a resolubilized aa-tRNA pellet) and all additional 
amino acids required to translate the peptide of choice, generally the 11-mer MVEVRH6. 
Whatever target amino acid was added to the aminoacylation (Val or fMet), this amino 
acid was not added separately to the in vitro translation mix. As such, the only source of 
the target amino acid during translation would be successfully acylated tRNAs from the 
aminoacylation reaction.  
We always ran negative controls in both the aminoacylation and in vitro translation 
reactions. Negative controls in the aminoacylation protocol lacked the cognate synthetase; 
either a non-cognate synthetase or no synthetase was added. Thus, negative controls lacked 
successfully acylated tRNAs. In vitro translation could have any of a number of negative 
controls. The negative control from the aminoacylation could be carried through as a 
negative control for in vitro translation. Additional negative control reactions could lack 
either the DNA template, one essential amino acid, or all amino acids.  
3.2.2 Key accomplishments and challenges  
During this assay, we improved the signal to noise ratio by an order of magnitude. 
Improvements to the protocol included deacylating purchased tRNAs, washing and drying 
the aa-tRNA pellet, optimizing the volume and solvent used to resolubilize the aa-tRNA 
pellet, adjusting the ratio of radiolabeled fMet and aa-tRNA storage. Unfortunately, having 
so many reagents in the aminoacylation and translation protocols meant it was difficult, 
expensive, and time-consuming to identify and correct sources of low-signal, high 
background, and data inconsistencies. Because our goal was to use this assay in concert 
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with our EF-Tu libraries, challenges quantifying our purified EF-Tu variants eventually 
made this protocol less immediately relevant and we moved on to an in vivo assay.  
3.2.3 Data 
3.2.3.1 Failed controls  
When we began work on the in vitro tRNA assay, the main problem was the ratio 
of signal to noise which was roughly one to one (Figure 3.2). Aminoacylation and in vitro 
translation experiments were always run with negative controls.  
 
Figure 3.2 Translation prior to optimization. Positive controls (blue bars) and 
negative controls (orange bars) are shown. Data generated by KG. 
The problem was that withholding the synthetase in the acylation reaction 
ultimately resulted in rates of translation similar to our samples which contained 
























Figure 3.3 Translation of MEVERH6 plasmid with tRNAVal variants. Graph shows a 
positive control (navy), translation with tRNAVal variants (blue), and a negative 
control (orange) (data by KG). 
3.2.3.2 Protocol optimization  
One possible reason for high background was that the tRNA used in the acylation 
protocol could have already been acylated. Thus, we started to optimize the protocol by 
deacylating purchased tRNAs and comparing results to tRNAs that were not deacylated. 
Both samples of tRNA, deacylated and untreated, were processed through the acylation 
and translation reactions. It appeared the deacylated tRNA gave better data and we decided 
to proceed using that method (Figure 3.4). However, the background during translation was 































































Figure 3.4 Deacylated tRNAs (blue bars) compared to purchased tRNA (orange 
bars). Graph shows amino acylation of deacylated tRNA with the cognate aaRS, 
with no aaRS added, and with a non-cognate aaRS (ValRS). 
 
Figure 3.5 Inconsistent valine translation. Translation with the correct ValRS (blue) 
and with the non-canonical aaRS (orange) and no aaRS (gray). Negative control has 
no aaRS or tRNA added. 
 
Moving forward, we decided to test a few possibilities at once. In the protocol, after 
acylating the tRNA with radiolabeled S-35 fMet, the solution was alcohol precipitated, 
pelleted down, and resolubilized in sodium acetate. We thought there might be residual 

























































































and increasing our background radiation. Residual radiation would make it appear as if we 
were getting translation with our negative control, but in reality, it might be contamination. 
To reduce contaminating radiation, we tried washing the pellet twice with 70% ethanol. 
We also speculated that the sodium acetate used to resolubilize the tRNA could be 
inhibiting the translation reactions. Perhaps we were not actually getting translation; 
perhaps the problem was not that background was too high, but rather that our signal was 
too low. This could account for our poor signal to noise ratio. As such, we also decided to 
try resolubilizing the pellet in water (Figure 3.6).  
 
Figure 3.6 Optimizing acylation protocol. Washing pelleted acylation and 
resolubilizing in sodium acetate (NaOAc) or water with cognate MetRS (blue bars) 
















































































Changes to experimental protocol
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Figure 3.7 Optimizing acylation of Met-RNA. Ratio of supernatant from reaction 
with MetRS versus supernatant from reaction with no RS. 
 
Figure 3.8 Translation Met results. Resolubilizing pellet in 5 or 50 μL of NaOAc or 
water. Cognate RS, MetRS, (blue). Non-cognate RS, ValRS, (orange). No RS added 
(gray). 
Some improvement was observed in the ratio of signal to noise (ratio of 
aminoacylation with aaRS versus no aaRS) (Figure 3.7). The data suggested that washing 
the pellet twice with 70% ethanol did help reduce background radiation. We also decided 
to try resolubilizing with different volumes. We were originally resolubilizing in 5μL of 
1mM NaOAc pH 5.2. We used a small volume to keep the aa-tRNA concentrated but 


























































Changes to acylation resolubilization 
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try using 50μL as a resolubilizing volume. We replicated the translation experiments 
comparing solvents (Figure 3.8).  
Additionally, we experimented using only radioactive fMet as compared to using 
both radioactive and cold Met together (Figure 3.9).  
 
Figure 3.9 Met translation with hot and cold Met and just hot Met. Also tested with 
various resolubilization volumes. Translation reactions with cognate MetRS (blue), 
non-cognate ValRS (orange), and no RS (gray). 
Following these experiments, we decided resolubilizing in 50μL gave significantly 
higher signal and also a better signal to noise ratio. The difference between using water 
and sodium acetate to resolubilize was less clear, but ultimately, it seemed that water was 
better. We decided to proceed using a combination of radioactive and cold Met which 
supported previous experiments that suggested using a mixture of hot and cold Met 
produced the best results. However, the results were still inconsistent.  
We decided to try changing the translation protocol to eliminate any possible 
contaminating amino acids or tRNAs in the NEB translation kit which might affect our 
results. The new protocol involved starting the translation reaction without our aa-tRNA 
or radioactive Met. Then, after one hour of translation, we interrupted the incubation and 
added our aminoacylated tRNA, all nineteen other tRNAs, and radioactive Met. We then 






















Differences in aminoacylation protocol 
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tRNAs or amino acids would be used up during the first hour of translation and peptides 
made during this time would not be radioactively labeled. Since radioactive Met was added 
later, only peptides made with our aminoacylated tRNA would be radioactively labeled. 
Note, these experiments were each run with four negative controls (Figure 3.10, Figure 
3.11).  
 
Figure 3.10 Val translation. Val concentration the same as Met (172.9 μM). 






























































































Changes to translation protocol
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Figure 3.11 Val translation. Translation reactions either incubated for 3-hours or 
translation mix had an interrupted incubation. 
We found that both signal and noise decreased using an interrupted translation 
protocol, improving background but not the ratio of signal to noise. However, the amount 
of peptide being synthesized was probably more accurate when the aminoacylation and 
Met were added part way through the incubation time. Therefore, we continued to use this 
new, interrupted translation protocol.  
Still hoping to improve the signal to noise ratio, we wondered if the aa-tRNA pellet 
was drying completely in 5 minutes. Even a small amount of ethanol left over from 
precipitating the aa-tRNA could inhibit translation. In an effort to dry the pellet completely, 
we decided to dry it for sixty minutes (Figure 3.12). Additionally, since it would greatly 
facilitate our experiments to be able to do aminoacylations a day or two before a translation, 
we decided to assess if aa-tRNAs were stable at -80 ˚C. We tested a variety of variables 
















































































































































































































Figure 3.12 Drying aa-tRNA pellet before translation. Translation with the correct 
MetRS (blue) and with the non-canonical aaRS (orange).  
 
Figure 3.13 Val translation. Assessing storage of aminoacylation reaction after 12 
hours, 4 days, or 5 days as a pellet or solution. 
The data suggested a sixty minute dry time improved translation. Additionally, it 
suggested that freezing the pellet also improved translation. As such, we continued to 
perform aminoacylations and translations on separate days, storing the aminoacylated 
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as a pellet or in solution without sacrificing activity. Granted, these data were still 
inconsistent.  
We tried to optimize the concentration of aaRS; however, these data had very high 
background again (Figure 3.14). Consequently, we repeated the experiment and 
encountered a different problem: scintillation counts were too low; no translation was 
occurring (Figure 3.15).  
 
Figure 3.14 Val translation failed with diluted RS. Translation with the correct 
ValRS diluted 1:4 (blue) and with the non-canonical MetRS diluted 1:4 (orange) 
and no aaRS (only buffer) (gray). 
 
Figure 3.15 Repeat 11.04.12 experiment with Met translation. Translation with the 
correct MetRS diluted 1:4 (blue) and with the non-canonical ValRS diluted 1:4 
(orange) and no aaRS (only buffer) (gray).  
































Since we had been constantly changing the protocol, we returned to previously used 
procedures which we knew worked, but translation was not occurring regardless of which 
procedure we used (Figure 3.16).  
 
Figure 3.16 Met translation failed. Tried varying protocol. Translation with correct 
MetRS (blue) and with non-canonical ValRS (orange). 
 
Figure 3.17 Comparing successful translation on left and failed translation results 
on right. Translation with all necessary components (blue bars) and translation 
lacking a cognate synthetase (orange bars) is shown. 
Comparison of these scintillation values representing successful translation (from 
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confirmed no translation was occurring (Figure 3.17). Radiation counts indicating 
successful translation should be >10,000 CPMs, but these values were under 200 CPMs. 
The simplest explanation was that the PURE translation kit had gone bad due to 
age, multiple freeze-thaw cycles, or contamination. In response we compared our 
translation kit (less tRNA) with another translation kit (less EF-Tu), which was 
successfully generating data, but the results were unchanged (Figure 3.18).  
 
Figure 3.18 Failed Met translation. Comparing translation kits. Aminoacylation 
with cognate RS (blue) and non-cognate RS (orange). 
 
Figure 3.19 Met aminoacylation. Comparing ratio of successful aminoacylation 
(blue bars) with unsuccessful aminoacylation (orange). 
Since the problem was not an expired translation kit, we tested the aminoacylation 
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Synthetase added to aminoacylation reaction
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cognate MetRS compared to aminoacylation with the non-cognate ValRS was low (Figure 
3.19). This ratio should be at least 10 (Figure 3.20).  
 
Figure 3.20 Comparing ratio of successful aminoacylation (blue bars) with 
unsuccessful aminoacylation (orange). Typically ratio should be 6 to 8. 
Since we knew at least part of the problem was with the aminoacylation, the most 
likely culprit was a stock or reagent that had gone bad. We made new, fresh stocks of 
ethanol, HEPES, dATP (which we moved to the -80 ˚C freezer instead of the -20 ˚C), 
MgCl2, KCl, PPase, DTT (from the Payne Lab), and new deacylated tRNA.  
In duplicate, we performed the experiment carefully following the exact procedure 
used the last day the experiment worked. The data seemed to suggest the old stock solutions 
were working, but the new stock solutions were not. We repeated the experiment only 
through aminoacylation, but the results were inconclusive. Since we were still unsure if the 
stocks were the issue, we repeated the experiment comparing old and new stocks with each 
of three scientists working only on her own experiments, but no experiments were 
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Figure 3.21 Met aminoacylation with old and new reagent stocks. Date of 
experiment listed with experimenter's initials. Cognate RS (blue/yellow), non-
cognate RS (orange/navy), no RS (gray/green).  
 
Figure 3.22 Ratio of aminoacylation with cognate (MetRS) compared to negative 
control (with ValRS). Experiments performed with old (blue) and new (orange) 
reagent stocks. Date of experiment listed with experimenter's initials. 
3.2.3.4 Aminoacylation starts working again 
We finally decided to perform an experiment selecting old or new batches of 
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Aminoacylation experiments by date
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HEPES buffer because we knew it had worked before. We used fresh stocks of MgCl2 and 
KCl because we started using molecular grade water part way through the fall and we knew 
the newer stocks had been made with molecular grade water. We chose to use ATP from 
the -80 ˚C because we thought the ATP stock in the -20 ˚C might have precipitated before 
it had been aliquoted. We used a fresh batch of deacylated tRNA and new ppase because 
the ppase was usually liquid in the -20 ˚C and the old ppase had frozen solid. We used the 
original protocol from the last day the experiment had worked. We resolubilized the 
aminoacylated reactions in water or in 1mM sodium acetate (pH ~4). We performed each 
experiment in triplicate. The experiment was successful. However, we could not 
definitively explain why it had started working. We decided to try to recreate the bad results 
we were getting when the aminoacylation was not working by using different stocks of 
HEPES buffer, dATP, and PPase. Unexpectedly, these experiments were also successful 
(Figure 3.23). All results indicated the aminoacylation had been successful with an average 
signal to noise ratio of 20:1, possibly the best ratio we had achieved (Figure 3.24).  
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Figure 3.23 Successful Met aminoacylation. Acylation with cognate MetRS (blue) 
and non-cognate ValRS (orange). Experiments listed with date. 
 
Figure 3.24 Ratio of aminoacylation with cognate (MetRS) to non-cognate (ValRS). 
We were ultimately unable to intentionally sabotage the experiment; however, we 
theorized the culprit may have been a bad batch of tRNA. Since we had used up that batch, 
we were unable to confirm this theory, but during a discussion with Dr. Loren Williams, 
he mentioned his lab often had problems with tRNA and they always ran new purchases 
out on a gel to make sure they had intact tRNA and not only fragments. Supporting this 
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In light of these experiments, it became clear the in vitro assay had challenges that 




CHAPTER 4. OPTIMIZING THE IN VITRO ASSAY FOR EF-TU  
Herein we discuss optimization of the translation protocol specifically for work with 
EF-Tu variants. While similar, this data does not repeat data presented in other chapters. 
The in vitro translation experiments were performed with a kit that lacked EF-Tu and 
amino acids which is similar to but different from the kit used in the previous chapter. We 
cannot necessarily assume the in vitro translation kit without EF-Tu will react the same as 
the kit without tRNAs and any differences are critical for us to note.  
 Optimizing assay  
4.1.1 Experimental protocols  
The in vitro assay used a custom PURE translation kit (NEB) from which EF-Tus 
and amino acids had been withheld. Translated peptides had an S-35 radioactive tag on the 
initiating fMet and were purified via affinity chromatography on Ni-NTA columns. As a 
result, the quantity of translated peptide is directly related to scintillation (CPM). Although 
this assay ultimately posed too many challenges to be overcome, it had a number of 
advantages over in vivo assays. First, host organism viability was not a concern. Second, 
we could characterize variants’ activity with practically any ncAA with no regard for its 
permeability across the cell membrane and with minimal concern for bioavailability, 
toxicity, or solubility. Third, we could control (at least in theory) the presence of 
endogenous translation components.  
4.1.2 Key achievements and challenges  
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The in vitro translation assay posed a number of challenges, the most pressing of 
which was high background. We worked to optimize the DNA template (including codon 
selection and concentration), amino acid concentration, the ratio of cold to radiolabeled 
methionine, and reaction volume. By optimizing the protocol, we successfully reduced 
background by reducing contaminating amino acids and tRNAs. We also improved 
reproducibility by improving consistency of ribosome allocation in the assay. Via mass 
spectrometry we also confirmed that codon selection is important. We attempted to pursue 
a theory of codon:anticodon mispairing in in vitro translation but results were inconsistent, 
and this was abandoned in favor of prioritizing the main focus of the project, EF-Tu 
engineering.  
Challenges that were not readily overcome included a highly thermo-unstable 
radio-compound. This was eventually exchanged for a more thermostable formulation. We 
also witnessed extremely low translation rates for ancestral proteins and low 
reproducibility which made it difficult to draw conclusions (this data was generated by Dr. 
Cole). An additional challenge was normalizing EF-Tu concentrations. Since our purified 
EF-Tus contained contaminating peptide product, Bradford protein assays were not 
applicable and it was difficult to quantify the concentration of only the EF-Tu variant.  
4.1.3 Failed control reactions  
Our first challenge was getting consistently reliable results from control 
experiments, especially negative control reactions. Alongside each experiment, we ran a 
series of negative controls. The negative controls involved one of several options: 
withholding one amino acid required for peptide synthesis, withholding all amino acids 
from the translation reaction, or withholding the DNA template from the reaction. We 
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expected all these negative controls to have similar, low signal, but this was not the case. 
When we withheld all amino acids or the DNA template from translation, the results 
matched our expectations, and we saw very low levels of translation However, when we 
withheld only one necessary amino acid (in this case valine) we saw high translation levels 
of peptide that were very similar to the positive control (Figure 4.1). These results 
suggested that peptide translation was happening even when we withheld a necessary 
amino acid from the translation system. Initially, we used the peptide MVVMH6 in which 
valine was the amino acid of interest.  
 
Figure 4.1 Transformation of MVVMH6 plasmid. Background (orange bars) in 
which the amino acid valine has been withheld is equal to positive control (blue 
bars) in which all necessary amino acids have been added. 
We decided to tackle the problem using multiple approaches. Our first strategy was 
to optimize the amino acid concentration. We thought one possible explanation was that 
when valine was withheld, another amino acid was being translated at that codon in lieu of 
valine (Figure 4.2). We found that diluting the amino acid concentration did not result in a 
better signal to background ratio; however, we did learn we could reduce the amino acid 
concentration by a factor of ten and still have similar results. In these results, our negative 
control was significantly lower than in some other experiments. However, it returned to 




















a ten-fold difference in CMP between signal and background) as well as consistence. As 
such, this did not completely solve our problem with high background, but did provide 
additional information.  
 
Figure 4.2 Optimizing amino acid concentration. Translation with all amino acids 
(blue bars) and translation lacking valine (orange bars). 
Concurrently, we experimented with using non-radiolabeled methionine in addition 
to only radiolabeled methionine (Figure 4.3). We found using a mixture of both 
radiolabeled and non-radiolabeled methionine resulted in a much better ratio of signal to 
background (Figure 4.4Figure 4.3).  
 
Figure 4.3 Translation either with both hot and cold methionine or with only hot 







































Sources of methionine in translation 
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Figure 4.4 Ratio of signal to background with either both hot and cold methionine 
or only hot methionine. 
Another theory was that radioactive methionine was being translated at the valine 
codon. Were that the case, each peptide in the negative control experiments would have 
multiple molecules of hot methionine which would increase background. If this were the 
case and radioactive methionine was going in for the two valines, only one third the number 
of peptides would need to be translated to give the same signal as our experimental 
reactions. Additionally, another possibility was that when valine was withheld, the system 
was not initiating translation at the first methionine, but rather at the second, translating 
MH6 instead of MVVMH6. We addressed both possibilities by designing a new peptide, an 
11-mer MVEVRH6, but background was still high.  
4.1.4 Optimizing DNA template and follow up experiments  
We wondered if a full-length protein would also have high background. A full-
length protein would have many valines that needed to be translated and would also have 
different valine codons for the translation machinery to read-through. This experiment 
seemed to give us accurate results: significant translation occurred with all twenty amino 
acids and withholding valine resulted in very low yields (Figure 4.5). At this point, we 
















translated a short peptide. We thought perhaps the problem was the valine codon we chose. 
Perhaps a different amino acid was going in for valine. We noticed the Val[GTG] and 
Met[ATG] codons had only one different nucleotide so we theorized that perhaps 
methionine was going in at the valine codon(s). A mispairing between a tRNAMet anticodon 
and the valine codon does not follow normal theories of anti-codon:codon wobble pairing; 
however, because the in vitro translation kit does not contain all translation components 
that are in the cell, it seems possible it may not follow the same rules regarding codon:anti-
codon wobble.  
 
Figure 4.5 Translation of 11-mer MVEVRH6 peptide and EF-Tu protein. 
Background (orange bars) is equal to signal (blue bar) for peptide. Background 
(yellow) is as expected relative to positive control (navy bar) for EF-Tu protein. 
We tested this theory by generating four new DNA templates, four variants of 
MVH6, each with one of valine’s four codons (GTT, GTC, GTA, GTG), as well as a 
control, MAH6, in which alanine’s codon GCA was used (Figure 4.6). Results showed we 
only got high background with Val[GTG]; when valine was withheld, all other codons 
showed low translation on par with MAH6 (for which alanine was withheld). The negative 



























DNA template and amino acids added
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methionine was being incorporated at the valine position when the Val[GTG] codon was 
used, since the codons differed by only one nucleotide.  
 
Figure 4.6 Testing different valine codons in DNA template for peptide translation. 
Template with alanine in lieu of valine is used as a control. Amino acids added were 
either MVH (blue bars) or MH (orange bars). 
Using mass spectrometry, we confirmed that methionine was going in for valine at 
the Val[GTG] codon. Because in vitro translation does not contain all components of in 
vivo translation, it is possible codon:anti-codon wobble pairing is different in vitro than in 
vivo. It is relevant to note that although researchers are familiar with differences between 
in vitro and in vivo translation, why we see these differences is not understood; however, 
observing differences is not unusual. When we translated MV[GTG]H6 without valine, the 
resulting peptide had a mass consistent with formyl-MMH6 and lacked a peak for formyl-
MVH6. However, when valine was included in the reaction, a peak was observed consistent 
with the mass of formyl-MVH6 and no peak was observed for formyl-MMH6. A control 
reaction using no amino acids showed no peaks consistent with either peptide (Figure 4.7). 
It is important to note that the in vitro translation performed with the radiolabeled Met and 
the mass spectrometry data are not actually replicates; although we thought so at the time. 






















prepare peptides for mass spectrometry, these peptides were generated with regular Met 
and thus did not contain Val.  
 
Figure 4.7 Mass spectrometry.  Panel A shows a peak at 550 corresponding to 
fMVH6 (m=1100), panel B is a negative control, and panel C shows a peak at 566 
corresponding to fMMH6 (m=1132). 
 
Figure 4.8 Translation of MVEVRH6-2 DNA template in which no codons share 
more than one nucleotide. Background (gray bars) had no amino acids added, the 
negative controls (orange bars) lack valine, signal (blue bars) show peptide 
translation. 
Based on the results indicating that the valine codon choice was critical to 
maintaining low background, we designed a new template, MVEVRH6-2, with no codons 
that shared more than one base in a particular position: M[ATG]; V[GTT]; E[GAA]; 
















observed good reproducibility and low background. Withholding valine resulted in only 
slightly higher readings than when no amino acids were included at all (Figure 4.8). 
4.1.5 Optimizing assay protocol  
Now that all experimental controls were working, we worked to improve 
reproducibility. We tested different DNA template concentrations and learned quantities 
as low as 17.5 ng per reaction saturated translation (Figure 4.9). 
 
Figure 4.9 Translation with different concentrations of DNA template. Blue bars 
contain all necessary amino acids; orange bars lack valine. 
We noticed that radiation values steadily declined from the first sample through the 
last. Each day, we ran several replicates simultaneously in separate Eppendorf tubes. 
Throughout the experiment, the tubes were treated (a solution was added or procedure was 
performed) in the same order. Even though all tubes were replicates of the same 
experiment, the first tube consistently had higher radiation levels with levels steadily 
decreasing through the last tube.  
One possible explanation for the observed inconsistency was that some of the 
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other samples. To test if the timing was the critical factor leading to inconsistent results, 
we intentionally allowed the experiment to sit for two minutes at various points in the 
procedure; however, intentionally pausing the experiment made no difference in the results 
(Figure 4.10). We would have expected any difference in CPM among samples to more 
dramatic than usual since we intentionally allowed the samples to sit for longer than they 
would in a normal procedure.  
 
Figure 4.10 Translation paused for two minutes at different points in protocol. 
Another possibility had to do with aliquoting a master mix to the tubes. During the 
protocol, a master mix of the translation solution was made for the day’s experiments. This 
solution was then aliquoted to individual tubes for the various experiments and controls. It 
was possible the tubes were not getting equal amounts of translation components. 
Specifically, ribosomes are known to sink in the solution. Since the ribosomes in the in 
vitro translation kit have limited turnover, the number of ribosomes aliquoted to each tube 
could affect translation rates. More ribosomes would result in more peptide production 
reflected by higher radiation values. To test this theory, we implemented adjustments in 
the protocol to ensure a homogeneous suspension of the translation components when we 






















To further improve reproducibility, we tested increasing the reaction volume (from 
5uL to 6uL total volume) (Figure 4.11). Pipetting larger volumes could help improve 
pipetting accuracy. Increasing the volume did not show any effect on the results and 
allowed us to add larger volumes of some solutions.  
 
Figure 4.11 Translation with different volumes. 
Although our translation kits were ordered without amino acids or EF-Tu, it was 
still possible some contaminating aa-tRNAs or amino acids were in the NEB kit solutions. 
We thought these contaminating amino acids might result in an increase in background 
signal. Adding no amino acids, we ran an experiment where we stopped translation a 
different time points. We found that despite withholding amino acids from translation, 
samples still showed translation during the first sixty minutes of the reaction (a normal 
reaction time was three hours) (Figure 4.12). This indicated it took approximately sixty 
minutes for any contaminating amino acids to be translated into peptides. This led to an 
adjustment in the experimental protocol; we decided to use an interrupted incubation 
period. We would incubate the solution for sixty minutes, then add radioactive methionine 
and finish the incubation. We found this strategy significantly reduced background. 


















We decided to continue using this protocol because we thought even though the signal was 
lower, the results probably more accurately represented amount of peptide synthesized.  
 
Figure 4.12 Timecourse of translation. Measure of peptide production relative to 
time of translation. Blue bars contain all needed amino acids; orange bars lack 
valine. 
4.1.6 Different codons in the DNA template  
After we optimized the translation protocol, we were intrigued by the idea that 
codon:anticodon wobble pairing followed different rules in vitro than in vivo. Recall that 
we found Met[ATG] was able to be translated at a Val[GTG] codon. The Met-tRNAMet 
was mispairing in the first position, not the last as with traditional wobble pairing. Curious 
to know if a general rule could be identified, we synthesized additional DNA templates 
exploring codons that had two nucleotides in common with Met[ATG]. Codons explored 
included Ile[ATT, ATC, ATA], Leu[CTG, TTG, TTA, CTT, CTC, CTA], Lys[AAG, 
AAA], Thr[ACG, ACT, ACA, ACC], and Arg[AGG, CGT, CGC, CGA, CGG, AGA]. 
Each codon was inserted into a MXH6 DNA template. Since these DNA templates were 
very short, primers were ordered, amplified, digested, and ligated into a digested 








1 2 1 2 1 2 1 2 3 4 1 2 3 4 1 2 3 4









Time of translation incubation
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We first tested leucine codons, CTG, TTG, TTA, and CTA (Figure 4.13). We 
expected methionine would go in for CUG and we would see translation even if leucine 
were withheld from the reaction. However, when we translated the peptide MLH6, all 
leucine codons had low background. Although Leu[CUG] had higher background, it was 
not high enough to indicate significant Met incorporation. 
 
Figure 4.13 Translation of DNA templates containing different Leu codons. Blue 
bars are samples that contain Leu, orange bars lack Leu, and gray bars have no 
amino acids added. 
   
Figure 4.14 Translation of DNA templates containing different Lys codons, AAA 
and AAG. Blue bars contain Lys, orange bars lack Lys, and gray bars have no 
amino acids added. 
We also tested lysine which we expected to have methionine misincorporation at 


































no evidence of methionine misincorporation when lysine was withheld from the reaction 
(Figure 4.14).  
Later, we learned that the radiolabeled methionine contains valine and alanine in 
an approximate 2:1 molar ratio (valine or alanine to methionine). This explains, in part, 
why we struggled with the in vitro assay. The decision to use valine analogs was perhaps 
uninformed despite the advantage that tRNAVal does not require posttranslational 
modifications (the driving force behind the decision to test valine analogs).  
 Follow up with EF-4A 
Following the experiments listed above, the in vitro assay was dropped due to a 
litany of challenges including consistently poor reproducibility and the inability to 
normalize EF-Tu concentrations (see below for full explanation). However, after 
generating data indicating EF-4A was a viable variant, we returned to the in vitro assay to 
assess EF-4A’s capabilities with other ncAAs. It is relevant to note, the radio-isotope used 
was highly thermo-unstable and as such, over the course of three months, we were unable 
to generate data. In detail, the radio-compound was highly volatile which resulted in 
significant contamination issues. Each decontamination effort required a freeze-thaw of the 
compound which resulted in complete degradation each time.  
4.2.1 New DNA templates  
As stated, after finding out variant EF4A had activity with Sep, we moved to the in 
vitro assay to assay its activity with other ncAAs that are, to varying degrees, compatible 
with wild type tRNA and aaRSs.32, 51 As such, we hoped that EF4A would be able to 
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improve upon ncAA translation. We were looking for increased translation when EF4A 
was added to translation, as compared to ncAA translation with only wild type EF.  



















Val GTT MVEVRH6  
In lab we had ncAAs which could go in for either Ala, Arg, Glu, Ile, Leu, Lys, Phe, 
Thr, Trp, Tyr, or Val.32, 51 We synthesized appropriate DNA templates using digestions and 
ligation (Table 4.1). Using only NEB EF-Tu, we first tested valine and alanine analogs, 
then glutamate, lysine, leucine, and arginine (Figure 4.15, Figure 4.16). We tested two 
different codons for Ile and Tyr so see if one of the codons had better signal to background 
ratio (Figure 4.17). Finally, we tested Phe, Thr, and Trp. For the Thr template, results were 
inconclusive so the experiments was repeated several times (Figure 4.18). Glu template 
was also replicated (Figure 4.22). We typically hope for values above 100,000 CPM to 
indicate successful translation. We hope for controls to be ten times lower.  
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Figure 4.15 Checking control reactions when using new DNA templates MVEVRH6 
and MAEARH6. Bars show translation with all necessary amino acids (blue), 
lacking valine or alanine, respectively (orange), and lacking all amino acids (gray). 
 
Figure 4.16 Checking control reactions when using new DNA templates. Bars show 
translation with all necessary amino acids (blue), lacking the target amino acid 
(orange), and lacking all amino acids (gray). 
 
Figure 4.17 Checking control reactions when using new DNA templates. Bars show 
translation with all necessary amino acids (blue), lacking the target amino acid 
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Figure 4.18 Checking control reactions when using new DNA templates. Bars show 
translation with all necessary amino acids (blue), lacking the target amino acid 
(orange), and lacking all amino acids (gray). 
4.2.2 Continued protocol optimization  
Under Dr. Cole’s direction, it had been decided that when pipetting such small 
volumes, the protocol would be to not wet the pipet tip and to expel the solution, pressing 
through to the second stop; however, we were not certain if this was the best technique. 
We ran experiments in which we expelled to the first stop with a dry tip, expelled to the 
second stop with a dry tip as we had been doing, and also first wet the pipet tip and then 
expelled to the first stop (Figure 4.19). During the time we had a number of issues with the 
assay not working (likely due to degradation of the radio-compound) but despite messy 
data, we decided wetting the tip first, then expelling to the first stop gave the best 
reproducibility. We based this analysis on the first set of data since the second set had really 
low translation rates, suggesting the radio-compound had degraded and thus we did not 
completely trust the results (Figure 4.20). Additional changes to the in vitro translation 
protocol included wetting the pipet tip when washing the Ni-NTA column with stop buffer 
and when eluting with imidazole. We also added a dry spin after the second wash with stop 



























Figure 4.19 Different pipette techniques. Bars show translation with all necessary 
amino acids. Colors are simply to guide the eye to replicates/averages. 
 
Figure 4.20 Different pipette techniques. Bars show translation with all necessary 
amino acids (blue) or missing valine (orange). 
EF-Tu variants were diluted and stored in a buffer solution. We tested if this buffer 
inhibited translation (as compared to water). The data translating the Val DNA template 
was messy so it was impossible to come to a firm conclusion (sometime standard deviations 
for reactions with water were smaller than reactions with the buffer and sometimes they 
were larger). We decided to try the experiment again with the Lys DNA template but values 















































































































































Figure 4.21 Assessing effect of buffer (blue bars) on translation as compared to 
water (orange bars). 
 Radio-compound formulation  
In detail, our radioactive Methionine, L-[35S] from Perkin Elmer (product number 
NEG009T005MC) is highly volatile because it is stored in beta-mercaptoethanol. As such, 
it must be stored in a container with activated charcoal in the container as well as activated 
charcoal in dishes in the freezer where it is located. It is also highly temperature sensitive 
and if warmed above -20 ˚C will degrade to methionine sulfoxide-[35S]. Storage at -80 ˚C 
is preferable, but storage at -20 ˚C is acceptable (which is what was used).  
However, Perkin Elmer developed another product, EasyTagTM Methionine, L-
[35S] (produce number NEG709A500UC ) which is stored in a stabilized aqueous solution. 
This formulation has added stabilizers as well as a blue dye, tricine, and β-mercaptoethanol. 
It is stable at room temperature and can be stored at 4 oC. For long-term storage, -20 oC is 































































































































DNA templates; Buffer or water added
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These products have identical concentration of methionine. The concentration of 
radiation is very similar (11 mCi/mL and 10.25 mCi/mL for NEG009T005MC and 
NEG709A500UC, respectively).  
It seemed translation with the new methionine worked well, however, it did not 
match results from earlier experiments (Figure 4.22).  
 
Figure 4.22 Translation with new, thermo-stable methionine. Bars show translation 
with all necessary amino acids (blue), lacking the target amino acid (orange), and 
lacking all amino acids (gray). 
 Normalizing EF-Tu concentration  
In general it is relevant to note that it was difficult to normalize concentrations of 
EF-Tus purified in house. In order to use our purified EF-Tus, we had to address the 
problem of not being able to quantify the concentration of our EF-Tu variants. One problem 
we ran into was standardizing the concentration of our EF-Tu variants. We couldn’t use a 
Bradford assay to determine the EF-Tu concentration because our EF-Tu variants had 
protein contamination from an unknown source and Bradford assays measure total protein 
concentration. Since we had data that indicated a wide range of EF-Tu concentration was 
acceptable in the in vitro assay with no effect on results, we decided to not expend 



























the project take in the future, we could perform a protein gel purification step followed by 
a Bradford assay. In this strategy, we would run the EF-Tu variant on a protein gel, excise 
the EF-Tu band, dissolve the gel, and resolubilize the protein. Then, it may be possible to 
perform a Bradford assay and get an accurate EF-Tu concentration of our variants.  
Alternatively, using a hexahistidine tag often purified contaminating proteins. We 
could purify the EF-Tu variants again and wash the affinity column using a buffer with a 
higher concentration of imidazole (e.g. 200mM). Some product would be lost, but the 
sample would likely be significantly more pure.  
 
Figure 4.23 Protein gel of EF-Tu variants at difference concentrations. Columns 
show (1) ladder (unfortunately, company is unknown); (2) the Hartman buffer 
(empty of proteins); NEB EF-Tu solution (3) at full centration, (4) 1:20x dilution, 
and (5) 1:40x dilution; in-house purified EF-4A (6) at full concentration and (7) 1:2 
dilution; and in-house purified wild type EF-Tu (8) at full concentration and (9) 1:2 
dilution. 
However, since translation remained consistent over a wide range of EF-Tu 
concentration, we decided to move on with translation experiments and quantify EF-Tu 
concentration later if it seemed more important. We knew that the NEB EF-Tu can be 
diluted 1:20 with no change in translation. As such, we decided to try to visually estimate 
the EF-Tu concentration on a protein gel. Run on a protein gel, the NEB EF-Tu diluted 
1         2           3         4          5          6          7          8         9 
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1:20 looked about the same as the EF4A diluted 1:2 and wild type EFcoli looked 






CHAPTER 5. ASSAYING EF-TU AND TRNA VARIANTS IN 
VIVO 
 Summary  
The first part of this chapter is excerpted from a manuscript. The latter part of the 
chapter details procedure, components, protocols, troubleshooting, and additional data 
from other libraries which did not lead to publications.  
 Successful ncAA incorporation  
5.2.1 ncAA-compatible EF-Tu variants 
To characterize the EF-Tu REAP-derived library, we used an amber codon 
suppression assay requiring the co-translational insertion of an ncAA at a premature amber 
stop codon. The target gene, chloramphenicol acyltransferase (CAT), contains an amber 
mutation at the permissive D112 position. CAT confers antibiotic resistance to E. coli 
resulting in an assay that directly correlates ncAA incorporation with cellular survival 
reported as half the maximal inhibitory concentration (IC50). Rates of survival above wild 
type EF-Tu (EF-coli) indicated the REAP-engineered EF-Tu variant could translate the 
ncAA with greater efficiency than EF-coli.  
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Figure 5.1 Chemical structure of o-phospho-L-serine. 
Phosphoserine (Sep) was a strong ncAA candidate for an engineered EF-Tu, 
because it is incompatible with wild type EF-Tu (Figure 5.1). To overcome this barrier, 
previous work developed an orthogonal triplet consisting of tRNASep, SepRS, and EF-Sep 
to enable co-translational insertion of Sep.17 This engineered triplet provided a platform 
for assessing the substrate compatibility of our modified EF-Tus irrespective of whether 
Sep or another amino acid was incorporated at the amber mutation. Our eight EF-Tu 




Figure 5.2 Characterization of REAP library variants. (A) Mutations made to 
generate REAP library. Protein variants are named by the number of mutations 
(four, eight, or twelve) followed by letters to distinguish among variants with four 
mutations. Sequence of wild type E. coli EF-Tu is shown for reference. (B) EF-Tu 
(gray) with amino acid residues mutated in variant EF-4A (inset). Protein is 
complexed with phenylalanine (orange) and tRNA (purple).  
Of the REAP-designed EF-Tu variants, variant EF-4A resulted in the highest levels 
of CAT translation. Other EF-Tu variants had limited compatibility with Sep, resulting in 
CAT translation that was either on par with or less efficient than EF-coli (Table 5.1). 
Although CAT expression was higher with EF-Sep than EF-4A, Sep translation, 
specifically, was not the aim of this effort. Rather, EF-4A presented a promising lead 
because it exhibited ncAA substrate compatibility without being specifically engineered 
for a particular ncAA. This behavior make EF-4A a good candidate for further analysis and 
development.  
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Table 5.1 IC50 values derived from REAP-derived EF-Tu variants. P-values are 
relative to EF-coli. 
EF-Tu variant n (replicates) mean st dev p-value 
EF-4B 3 0.0088 0.014 0.00001 
EF-4C 3 7.74 0.22 0.910813 
EF-4D 3 2.13 1.13 0.00001 
EF-4E 3 1.29 1.28 0.00001 
EF-4F 3 1.89 1.40 0.00001 
EF-8A 5 1.11 1.63 0.00001 
EF-12A 3 4.71 0.75 0.000669 
EF-K263A 3 5.90 0.28 0.015452 
EF-Sep 5 26.87 5.83 0.00001 
Variant EF-4A had four point mutations: N63A, D216A, K263A, and N273A 
(Figure 5.2). To determine which of these mutations contributed to ncAA compatibility, 
four single-mutation EF-Tu variants were generated: EF-N63A, EF-D216A, EF-K263A, 
and EF-N273A. Of these variants, EF-D216A showed improved efficiency of ncAA 
translation compared to EF-coli and EF-4A (Figure 5.3).  
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Figure 5.3 Characterization of single-mutant EF-Tu variants. In vivo suppression 
via EF-Tu variants with Sep-OTS (green) or without SepRS (blue) as measured by 
synthesis of CAT (measured by IC50 value). P values relative to EF-coli. 
Data generated by the EF-Tu library presented an opportunity to evaluate how 
effectively REAP identified sites that enhanced promiscuity, especially residue D216. Site 
216 was ranked within the top ten sites identified by Type II functional divergence and 
within the top 15% (out of 279 total residues) overall. Six sites selected for library 
development were ranked higher: V276, N273, S65, G275, F261, and E259, listed in order 
ranked. Of these residues, site N273 was also mutated in variant EF-4A. Although EF-
N273A was not as effective as EF-D216A or EF-4A, contrary to previous findings N273 
does have some impact in promiscuity, evidenced by additional data (Figure 5.3).52 As 
expected, while some residues identified by REAP do affect substrate compatibility, amino 
acid conservation is governed by a variety of factors (e.g., tertiary structure or solubility). 
Not all residues identified by REAP participate in protein function despite exhibiting strong 
signatures of functional divergence.  
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Upon reviewing the data more closely, it is relevant that despite screening more 
sequence space, these results parallel previous work implicating position 216 in efforts to 
broaden substrate compatibility.16 This may be a consequence of using distance 
discrimination, the prevailing strategy to engineer EF-Tu substrate affinity, to cull the 
REAP data. Although researchers routinely use external information (e.g., crystal 
structures) to guide amino acid selection, in this case being influenced by prior knowledge 
led to a conclusion similar to previous work. This observation suggests that part of REAP’s 
power lies in identifying residues not previously expected to contribute to function. 
Twenty-two residues, while more than earlier efforts, may have not been a sufficiently 
diverse group to examine.  
5.2.2 Mass spectrometry confirms substrate-promiscuous EF-Tu variants  
 76 
Table 5.2 A representative group of peptide spectra matched. A modified 
CAT112TAG gene was translated via EF-Tu variants EF-4A, EF-D216A, and EF-
Sep. A control wild-type CAT gene was also translated via EF-Sep and EF-coli. 
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Protein sequence used to generate CAT protein CAT112TAG wild-type CAT
 
Electrospray ionization mass spectrometry (chymotrypsin digestion) confirmed 
site-specific Sep incorporation. Results showed EF-4A and EF-D216A not only 
incorporated Sep but also serine at the permissive position. EF-D216A also incorporated 
Gln-tRNASep (Table 5.2). Serine and glutamine misincorporation at the amber codon could 
be explained either by a mischarged tRNASep being delivered to the ribosome or by a native 
aa-tRNA mispairing with the amber codon. If EF-Tu variants EF-4A and EF-D216A were 
incorporating canonical amino acids via a misacylated aa-tRNASep, it would indicate these 
EF-Tu variants are truly substrate-promiscuous, accepting both ncAA-acylated tRNAs as 
well as misacylated tRNAs. To confirm, we pursued both possible explanations for the 
mixed protein product. It is relevant to note, experimental controls reject the possibility of 
Sep post-translational dephosphorylation as a route to Ser112 incorporation. If a post-
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translational modification were responsible, Ser112 would be evident in the EF-Sep 
expressed CAT protein as well.  
Table 5.3 IC50 values. EF-Tu variants assayed without the SepRS gene. P-values are 
relative to EF-coli assayed without the SepRS gene. 
EF-Tu variant n (replicates) mean st dev p-value 
EF-K263A 3 2.08 2.65 0.000518 
EF-Sep 3 13.25 4.5 0.039082 
To determine whether a mischarged tRNASep or mispaired aa-tRNAs was 
responsible for serine incorporation, tRNASep and SepRS were withheld from translation 
in separate experiments. When SepRS was withheld, both EF-4A and EF-D216A were able 
to express a catalytically active target protein (Figure 5.3). Other variants showed low 
translation without SepRS (Table 5.3). This suggests tRNASep has cross-compatibility with 
native aaRSs and is being misacylated with serine. Supporting this conclusion, when 
tRNASep was withheld from the assay, no CAT expression was observed (5 μg/mL was the 
lowest concentration tested). This indicates a misacylated tRNASep is the mechanism by 
which serine is being misincorporated.  
These results confirmed variants EF-4A and EF-D216A are, in fact, substrate-
promiscuous. In contrast to wild type EF-Tu and EF-Sep, both REAP-developed variants 
will accept misacylated tRNAs and ncaa-tRNAs. This lack of discrimination suggests these 
EF-Tu variants could be promising in combination with other ncAAs. It also recommends 
them as platforms for development of additional EF-Tus with novel function, in the form 
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of either further enhanced promiscuity or alternate substrate specificity.40 Additionally, 
these data also emphasize the power of single mutations to EF-Tu. The REAP library was 
originally developed with each variant containing multiple mutations, a common strategy; 
however, these data suggest designing EF-Tu variants with single point mutations might 
be a more valuable strategy especially when seeking broad substrate compatibility.16  
While these data illustrate the development of promiscuous EF-Tu, it also 
introduces a possible objection to using a promiscuous EF-Tu: inaccurate translation of the 
target gene. While this may initially seem problematic, we argue this challenge is readily 
overcome by recent advances to OTS engineering. Our data confirmed this particular o-
tRNA (tRNASep) is cross-compatible with endogenous aaRSs.17 This indicates that 
misincorporation, while permitted by the EF-Tu, is actually caused by a cross-reactive 
OTS. While a substrate-specific EF-Tu variant, like EF-Sep, can prevent misincorporation, 
this strategy merely shifts the burden of accurate translation from the aaRS:tRNA pair to 
the EF-Tu. Additionally, it also fails to address the cross-compatible OTS as the underlying 
cause.  
Unfavorable consequences of cross-compatible OTSs (e.g., depressed host 
organism growth, inefficient multi-site ncAA incorporation) are well established.10 Since 
cross-reactive OTSs are a common obstacle to genetic expansion, recent articles advocate 
for more rigorous o-tRNAs and o-aaRS engineering.10, 11, 53, 54 Precise OTS engineering 
transfers the responsibility of accurate translation from the EF-Tu back to the aaRS:tRNA 
pair. This redistribution of labor mimics the design of cellular translation. In the cell, 
endogenous aaRS:tRNA pairs are unequivocally orthogonal to all other tRNAs and aaRSs. 
While wild type EF-Tu serves as a component of quality control, in point of fact, tRNA 
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misacylation rarely occurs.55 Consequently, the primary responsibility for accuracy during 
translation falls to the canonical aaRS:tRNA pairs, not downstream translation 
components. As such, it is not surprising that improving OTS orthogonality improves 
organismal growth and multi-site ncAA translation.10, 11 
By mirroring the native distribution of responsibilities, discrete OTSs that ensure 
accurate tRNA acylation pave the way for researchers to use translation components with 
expanded capabilities, including substrate-promiscuous EF-Tus. Were a rigorously 
engineered OTS used, there is no evidence a promiscuous EF-Tu would undermine 
accurate translation. Similarly, we would anticipate that synthetic acylation methods (e.g., 
flexizymes) to be compatible with a promiscuous EF-Tu.50  
5.2.3 Selected promiscuous EF-Tus improve organismal fitness  
While broad substrate acceptance is desirable in EF-Tu, there may be a limit to the 
degree of infidelity that it is possible for the cell to tolerate. A promiscuous EF-Tu must be 
sufficiently indiscriminate to readily accept ncaa-tRNAs; however, too promiscuous and it 
could interfere with translation of canonical amino acids. Were an engineered EF-Tu 
sufficiently competitive with native EF-Tu, the translation machinery may inaccurately 
translate genomic DNA. To examine the impact of a promiscuous EF-Tu on endogenous 
translation, we compared the effect of EF-Tu variants on organismal fitness.  
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Figure 5.4 Growth assays for EF-Tu variants expressed in BL21ΔserB cell line. 
Triplicate averages are shown for EF-4A (black triangles), EF-Sep (blue circles), 
and EF-coli (green diamonds). 
Table 5.4 Calculated parameters from growth curves fitted with a modified logistic 
growth model. Maximum specific growth rate was calculated based on x=t0. Lag 
time was calculated based on the line tangent to the fitted curve at x=t0. 
 
In order to evaluate the effect of a promiscuous EF-Tu on organismal fitness, we 
compared growth of cell line BL21ΔserB when expressing EF-coli, substrate-specific EF-
Sep, and the promiscuous variant EF-4A (Figure 5.4). Cultures expressing the substrate-
promiscuous EF-4A grew fastest with a shorter lag time before reaching an exponential 
growth phase, but both EF-Sep and EF-4A grew noticeably faster than cells expressing EF-
coli (Table 5.4). Parameters were calculated based on growth curves fitted with a modified 
logistic growth model that combined linear models for lower and upper regions of data 
(assuming an initial lag period and eventual asymptote) with a logistic model y = 
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1/(1+e^((t0-x)*A)) for the growth phase. In total, seven parameters were fit to each growth 
curve. Because the BL21ΔserB cell line lacks the gene encoding Sep phosphatase, growth 
curves could not be reproduced using an alternative engineered cell line (e.g., one in which 
the amber codon has been reassigned). 
To some extent, native EF-Tu is both substrate-specific and promiscuous. Because 
EF-Tu has proof-reading capabilities, by limiting its ability to check for misacylated aa-
tRNAs, a promiscuous EF-Tu may increase the rate of misincorporation of canonical amino 
acids. The cell’s translation apparatus has been finely tuned for unparalleled accuracy and 
speed. As such, expanding the capabilities of this carefully balanced system may have 
consequences impacting genome translation manifested as depressed organismal growth.  
However, unlike tRNAs and aaRSs, EF-Tu already exhibits a certain level of 
promiscuity. EF-Tu accepts all twenty canonical aa-tRNAs as substrates, which suggests 
expanding the substrate compatibility of EF-Tu may be within the natural limits of the 
translation apparatus.  
The growth curves indicate that a promiscuous EF-Tu does not negatively impact 
endogenous translation; in fact, it can actually decrease the fitness cost of expanding the 
genetic code. These data also indicate a promiscuous EF-Tu does not interfere with 
translation of the genome. Any misincorporation would have to be minimal so as to not 
impact host organism fitness. Hence, with evidence of the benefits, including reduced 
fitness cost, a promiscuous EF-Tu appears to be an asset to genetic code expansion with 
minimal drawbacks.  
 Materials and methods 
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5.3.1 REAP library  
The REAP alignment was generated using thirty-eight sequences from nineteen 
species of bacteria that express both EF-Tu and SelB. Due to a large discrepancy in average 
sequence length between EF-Tu and SelB sequences, we normalized the length of the 
thirty-eight selected sequences to create a more accurate phylogeny. Generally, twenty-
five residues were eliminated from the N-terminus of each SelB sequence and 343 residues 
were deleted from the C-terminus. For EF-Tu sequences, forty-seven were removed from 
the N-terminus; the C-terminus was not adjusted.  
REAP analysis was completed using DIVERGE2.0 software. The multiple 
sequence alignment was generated in Clustal Omega; the phylogeny was generated within 
DIVERGE2.0 (using a Poisson distribution). Output was calculated for Gu99, Gu01, and 
Type II. Residues that were cut from the N-terminus were evaluated by eye.  
5.3.2 In vivo assay 
Variants were assayed using a system for the co-translational insertion of Sep in 
vivo. This system included an orthogonal triplet, a tRNA (tRNASep), an aminoacyl-tRNASep 
synthetase (SepRS), and EF-Tu variant (EFSep) specifically engineered for Sep. These 
genes were located on two plasmids: pCAT112TAG-SepT (Addgene, plasmid number 
34624), and pKD-SepRS-EFSep (Addgene, plasmid number 34623). The EF-Tu variant 
EFSep was used as a positive control and the standard to which the REAP variants were 
compared. Wild type E. coli EF-Tu, which is not compatible with Sep, was used as a 
negative control. It is relevant to note that all experiments contained endogenous wild type 
EF-Tu. Cell lines BL21ΔserB (Addgene, bacterial strain number 34929) and Top10ΔserB 
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(Addgene, bacterial strain number 34928) were used. All plasmids and cell lines from 
Addgene were gifts from Jesse Rinehart and Dieter Söll.  
5.3.3 Calculate IC50 
Plasmids of choice (pKD and pCAT) were transformed into BL21ΔserB competent 
cells (Addgene, catalog number 34929). A single colony was selected, grown overnight, 
and made into glycerol freezer stocks (25% sterile glycerol, 25% sterile water, 50% 
bacteria culture). For each assay, glycerol freezer stocks were streaked out, a single colony 
was picked and grown ~24 hours. The culture was then diluted to OD600 0.15 in media 
supplemented with 2mM Sep, grown to OD600 0.6-0.8 and induced (0.5mM IPTG, Sigma-
Aldrich). Cultures were allowed to express for 20 hours then diluted in saline and plated, 
in duplicate, on petri dishes with a range of chloramphenicol (Thermo Fisher Scientific) 
concentrations. Colonies were counted daily.  
All liquid and solid cultures were grown at 30 ˚C. All liquid cultures were grown 
in LB media supplemented with 0.08% glucose. Kanamycin (25μg/mL, kanamycin sulfate, 
VWR), tetracycline (10 μg/mL, tetracycline Hydrochloride 98%, Alfa Aesar), and Sep (2 
mM, O-phospho-L-serine Sigma-Aldrich) were present in all liquid cultures and agar Petri 
dishes.  
5.3.4 Protein purification for mass spectrometry  
For mass spectrometry assays, a hexahistidine tag was added to the carboxyl-
terminus of the CAT112TAG gene (via Gibson assembly). The His-tag was added to the 
carboxyl-terminus to prevent truncated peptides from being purified. Appropriate glycerol 
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freezer stocks were made as described above. Glycerol freezer stocks were streaked out, a 
single colony was picked and grown overnight. Then, 1-1.5 mL starter culture was added 
to 0.5-3L media supplemented with 2mM Sep, grown to OD 0.6-0.8 and induced (0.5mM 
IPTG). Protein was expressed for 20 hours then spun down and frozen at -80 ˚C. Cultures 
were resuspended in 5mL BugBuster® (Protein Extraction Reagent EMD Millipore) and 
2.5 uL Benzeonase (250 U/uL purity >90% EMD Millipore) per 1 g cell pellet. 
Resuspended pullets were incubated, rocking, at room temperature for 60 minutes then 
spun down (11,419 x g). The supernatant for each sample was collected and applied to a 
Ni-NTA Superflow Column 12 x 1.5mL (Qiagen) using a vacuum manifold (QIAvac 24 
Plus, Qiagen). All filter sterilized buffers contained 50mM NaH2PO4 300mM NaCl pH 
8.0 with either 10, 20, or 500 mM imidazole. Columns were prepped by decanting the 
storage buffer, then applying 10mL 10 mM imidazole buffer. Next, 30mL of supernatant 
were applied to column, followed by 10mL of 20mM imidazole buffer. This step was 
repeated, applying 30mL supernatant followed by 10mL 20mM imidazole buffer, until all 
supernatant had been applied to the column, ending with 10mL 20mM imidazole buffer. 
Finally, protein was eluted in 0.5mL aliquots of 500mM imidazole buffer (4.5mL total). 
Eluate aliquots were run on an SDS-PAGE gel to estimate protein concentration in aliquots. 
When deemed necessary, aliquots were combined and concentrated using Spin-X UF 
500uL Centrifugal Concentrator, 10,000MWCO membrane (Corning) .  
Purified samples were digested with chymotrypsin and analyzed using ESI-MS (Q 
Exactive Plus, Thermo Scientific) with a Dionex nano-LC system in front to separate 
peptides. The wildtype sequence of CAT was also expressed and the amino acid sequence 
checked via mass spectrometry; as expected, only the wild type amino acid, aspartic acid, 
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was translated at position 112. Variants EF-coli, EF-N63A, EF-K263A, and EF-N273A 
were not analyzed using mass spectrometry because protein expression levels were too low 
to isolate purified CAT protein.  
5.3.5 Growth curves 
For each sample, glycerol freezer stocks were streaked out. Three colonies were 
selected from each plate and grown ~24 hours. The starter cultures were then diluted to 
OD600 0.15 in 200μL fresh media supplemented with 2mM Sep and 0.5mM IPTG. Samples 
were grown overnight with shaking (medium) in 96-well plates (black sides, clear bottom; 
Greiner Bio-One, catalog number 655096). A BioTekTM SynergyTM H4 Hybrid microplate 
reader (Thermo Fisher Scientific) measured absorbance (OD600) with pathlength correction 
every ten minutes.  
Three wells with only LB supplemented with glucose, antibiotics, Sep and IPTG 
served references for absorbance measurements. All liquid cultures were grown at 30 ˚C 
in LB media supplemented with 0.08% glucose, 25 μg/mL kanamycin, and 10 μg/mL 
tetracycline. 
 Additional data 
5.4.1 In vivo assay design  
The in vivo assay tested our EF-Tu variants compatibility with the ncAA, Sep. In 
vivo translation of the Sep in E. coli was accomplished by using an orthogonal triplet: a 
tRNA (tRNASep), synthetase (SepRS), and EF-Tu variant (EFSep) specific for the ncAA.17 
This particular ncAA was not compatible with wildtype E. coli EF-Tu but translation was 
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accomplished when an EF-Tu variant was engineered to accept Sep as a substrate. We 
purchased the necessary components, cell lines Top10ΔserB and BL21ΔserB as well as 
plasmids pKD-SepRS-EFSep and pCAT112TAG-SepT, to assess our EF-Tu libraries’ 
compatibility with this ncAA. These were a gift from the Soll and Rinehart labs (Addgene). 
EFSep was used as a positive control and the standard to which our variants were 
compared. Wild type E. coli EF-Tu, which is not compatible with Sep, was used as a 
negative control.  
Both SepRS and EFSep genes on the pKD-SepRS-EFSep plasmid (Kan resistant, 
grows at 30 deg.) are controlled by the lac promoter and expression can be induced via 
IPTG. The pCAT112TAG-SepT plasmid (Tet resistant) has the CAT gene with an amber 
stop codon at the permissive position, Asp112, along with the tRNASep (SepT). When Sep 
is translated, the CAT gene is expressed and imparts chloramphenicol resistance to the 
bacteria, meaning an IC50 can be calculated and directly related to the efficiency with which 
Sep is incorporated. All assays were performed in BL21ΔserB cells.  
5.4.2 Cloning EF-Tu and tRNA variants  
We excised the EFSep gene and cloned EF-Tu variants from our ASR, consensus, 
REAP, and transplantation libraries into the pKD-SepRS plasmid using a restriction 
enzyme digestion and ligation and confirmed via sequencing. Dr. Cole ordered primers to 
add relevant digestion sites to the EF-Tu genes via PCR and we successfully cloned all EF-
Tu variants from the ASR, REAP, and consensus libraries into the pKD-SepRS plasmid 
for use with the in vivo assay. The first ligation was not successful. We ran a serious of 
controls and confirmed that the ligation reagents were active. We found a one to one molar 
ratio of insert to vector resulted in successful ligations. It is worthy of note that one ASR 
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variant, 209, was not carried through the in vivo assay because it contains one of the 
digestion sites in the middle of the gene.  
We also mutated tRNASep gene based on unpublished work (Gaucher Lab) that 
indicates the position of a G-U wobble pair affects the strength of aa-tRNA:EF-Tu 
association. Although optimization of the PCR annealing temperature and transformation 
protocol was time-consuming, Agilent’s QuikChange II Site-Directed Mutagenesis kit was 
used to generate these variants. It is worth noting that both NovaBlue and XL1-Blue 
supercompetent cells are Tet resistant and thus incompatible with the pCAT plasmid. We 
moved a G-U wobble pair to various positions in the T-arm and acceptor stem of the tRNA 
to perturb the strength of Sep-tRNASep:EF-Tu association. We also made one variant that 
lacked the tRNASep as a control.  
During this process we learned that although these plasmids are high copy, 
minipreps resulted in low plasmid concentration which often resulted in poor sequencing 
reads. As such, we used larger culture volumes for minipreps and also started submitting 
higher plasmid DNA concentrations for sequencing. Primer concentrations were also 
optimized for sequencing submissions.  
5.4.3 Assay implementation  
In preparation for assays, we made chemically competent cells of both Top10ΔserB 
and BL21ΔserB cell lines. BL21ΔserB chemically competent cells containing plasmids 
(either pKD-SepRS-EFSep or pCAT112TAG-SepT) were also made. Stocks of Tet, Kan, 
Cmp, and Sep. All stocks were filter sterilized (0.22um) except the Sep stock as the ncAA 
has low solubility in water and would have been filtered out of solution. Contamination 
from Sep was never an issue.  
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The published methods were incomplete. By contacting the Rinehart Lab, over 
three months we learned that 1) they use the BL21ΔserB cell line for expression, not 
Top10ΔserB as stated in the publication, 2) they expressed cultures for about 20 hours at 
30 degrees, and 3) they used LB liquid media supplemented with 0.08% glucose. Along 
the way, we learned to omit IPTG in the assay plates. Through trial and error we learned 
the IPTG concentration required for the plate assay (unreported) was roughly ten times 
than what was reported for phospho-protein expression (0.05 and 0.1 mM).  
Another set of challenges with developing a working protocol related to how slowly 
these cultures grew. First, these cultures did not reach confluency in the 12-18 hours a 
typical overnight cultures would take. Our cultures took about 24-30 hours to grow to 
confluency. Second, overnight starter cultures worked best if diluted to only 0.15 OD600 
whereas we usually diluted to roughly 0.001 OD600 in other expression protocols. Third, 
control plates took 30-48 hours to grow and assay plates took four to seven days even with 
low Cmp concentrations. As a reference point, doubling time in liquid media was roughly 
70 minutes but depending on the variant could be over 100 minutes. These extended growth 
times meant that we did not think the protocol was working when in fact we just weren’t 
waiting long enough for the cultures to grow.  
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Figure 5.5 Growth of tRNASep variants on Cmp plates (5 μg/mL). Data is average 
number of colonies on two plates (same liquid culture). Cultures diluted in LB 
(blue) or saline (orange) before plating. Counted Day 3. 
Reproducibility was also a significant problem. Eventually, the Rinehart and Söll 
Labs released an updated phospho-protein kit. While this kit was not relevant to assay EF-
Tus, it had an in-depth protocol which provided insight into the methods these labs used to 
develop their assays. We not only learned how slowly these bacteria strains grow, but also 
that reproducibility was a significant problem. The revised protocol recommended making 
glycerol freezer stocks of transformations, then streaking out from these stocks for each 
assay. In typical practice, a fresh transformation results in improved protein expression; 
using glycerol stocks significantly improved reproducibility.  
Our first goal was to translate Sep and replicate the published data. We optimized 
growth temperatures, induction conditions, IPTG concentration, expression time, and 
plating and dilution procedures. Following recommendations from the developing lab, we 
made glycerol freezer stocks from overnight cultures grown from fresh transformations. 
Glycerol stocks contained a 1:1 ratio of overnight bacteria culture and sterile 50% glycerol 
solution. These glycerol freezer stocks were streaked out and grown 30 hours then colonies 


















































Chronologically, the first challenge with the in vivo assay was that the published 
methods section which accompanied the phospho-protein translation kit (Addgene) was 
not sufficient to reproduce the published data nor to synthesize phospho-proteins. The 
Torres Lab (Georgia Tech) also struggled with this kit. As such, the protocol used was 
developed in-house; we optimized growth temperature, cell line selection, induction 
procedure, expression times, reproducibility, and plating and dilution technique. It is 
relevant to note the bacteria strains used grow slowly (in both liquid and plated cultures). 
As such, we also assayed addition protein libraries including ASR (12 variants), consensus 
(2 variants), and the binding-site transplantation library (15 variants) although these data 
did not result in a publication.  
The following data were generated from efforts to replicate published results and 
improve reproducibility. Since data is reported at IC50 values, we needed a reliable 
technique to dilute and plate bacteria cultures following induction. We tried diluting in LB 
and saline and found that diluting in saline offered significantly better reproducibility 
(Figure 5.5).  
We also tried to increase antibiotic concentrations (Figure 5.6). Several people in 
lab were observing tiny colonies on plates. It seems possible now that we had bacteriophage 
contamination but at the time increasing Kan was one attempted strategy. What we learned 
as that doubling the concentration of Kan seemed to improve growth, but did not affect the 
tiny colonies either. Eventually, we were able to eliminate the contamination issue, but 
increasing antibiotic concentrations did not help.  
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Figure 5.6 Testing increasing antibiotic concentration. Increased kanamycin 
concentration from 25 μg/mL (blue bars) to 50 μg/mL (orange bars). Data collected 
on day 3. 
We also examined the concentration of IPTG used to induce gene expression 
(Figure 5.7). We found it did not make much difference so we continued to use 0.5mM 
IPTG. 
 
Figure 5.7 Testing concentrations of IPTG. Concentrations tested included 0.1mM 
(light blue), 0.5mM (orange), 0.75mM (gray), 1mM (yellow), 5mM (navy). Data 




















































































































Figure 5.8 Trying to measure background. Samples contained (+) or lacked (-) 
IPTG (I) and phosphoserine (S). Samples were plated on plates containing 
phosphoserine (orange bars) and lacking phosphoserine (blue bars). Data collected 
on day 2. 
We also attempted to run a series of controls with or without the ncAA (Sep) and 
with or without IPTG (Figure 5.8). Growth was consistently higher when Sep was added 
to plates (orange bars). As such, we decided to always add Sep to assay plates. These data 
also indicate our operon is leaky which is not especially surprising. What was surprising 
was that growth rates increased when Sep was withheld from the expression culture 
suggesting that endogenous Sep is more bioavailable and that Sep up-take was somehow 
detrimental to growth. However, because ncAAs are most commonly added to liquid 
culture prior to induction, we continued with that method. We also continued to induce 


























































































Figure 5.9 Varying Sep concentration. Samples with Sep only in liquid media (not 
plates) contained 0.5 (blue), 2 (orange), or 4 (gray) mM Sep. Reactions with Sep in 
both liquid and solid media contained 0.5 (yellow), 2 (navy), 4 (green) mM Sep. 
We also tried different Sep concentrations in both liquid LB media and solid agar 
plates. These results confirm that having Sep in the plates greatly improved growth rates, 
but they do not consistently suggest a specific Sep concentration is most desirable. Most 
data suggests 0.5 mM is the ideal concentration but EF-4A (which we are trying to 
optimize) suggests 4 mM is better. Other articles suggest 1 mM is best. We decided to 
continue to use 2 mM which is recommended by the article (Figure 5.9).  
Still trying to replicate published data, we tested EF-Sep and EF-coli (Figure 5.10). 
EF-coli, our negative control, is in keeping with published values but EF-Sep, a standard 
for comparison, is lower than reported.17 Eventually, we were able to increase EF-Sep IC50 
by greatly increasing the concentration of IPTG used but it minimized the difference 


























































Figure 5.10 IC50 of positive control, phosphoserine, (blue bars) and negative control, 
coli, (orange bars). Phosphoserine data from Day 6. Coli data from Day 7. 
 
Figure 5.11 OD600 when induced versus IC50 for binding-site library. Assays to 
determine if there is an ideal OD600 at which induction would produce a higher IC50. 
We also tried to optimize our OD600 at induction, but our system did not seem to be 
significantly sensitive (Figure 5.11). There was no obvious correlation between OD600 and 
the IC50. At this point, we decided to progress with assaying the EF-Tu variants. The 
binding-site transplantation library showed no significant hits (Figure 5.12). We did not 
find any hits in the ASR library (Figure 5.13). However, we had a hit, EF-4A, in the REAP 


















































of EF-4A as a possible ncAA-compatible variant. We returned to the in vitro assay (see 
Chapter 4) but were unable to generate results.  
 
Figure 5.12 IC50 of EF-Tu variants from binding-site library. Error bars are 
standard deviation. Data collected day5. 
 
Figure 5.13 IC50 of select ancestral and consensus EF variants. These variants 
showed the most promise in previous studies. EF coli is the negative control. Data 
collected on day 10. 
Following our in vitro efforts, we were requested to try to expand the in vivo assay 
to assay EF-4A with other ncAAs. We agreed to work for three months trying to expand 
the in vivo work in such a way as to assay EF4A in vivo against tyrosine analogs. The new 
















































































aaRS:tRNA pairs developed by the Schultz lab. We began using SOE to make the genes 
and Gibson assembly to clone them. Unfortunately, although eventually we were able to 
make these techniques work, starting them up in lab from scratch took time. The plasmids 
we worked with replicated slowly, grew at lower temperatures, and the first two or three 
protocols developed for Gibson assembly failed. By the time trouble shooting was done, 
more than three months had passed and we were eager to move back to the original EF4A 
data and try to write the relevant article. However, first we were requested to initiate the 
Gaucher Lab’s involvement in the Multidisciplinary University Research Initiative 
(MURI) and train a new postdoctoral fellow for that grant (see Chapter 6).  
 
Figure 5.14 IC50 of REAP EF-Tu variants. Data is preliminary. Variant 4F not 












CHAPTER 6. INITIATING MURI GRANT IN LAB  
We initiated research on a Multidisciplinary University Research Initiative 
(MURI), from the Department of Defense including transfer of materials and 
communication of results via video conference calls. The aim of this project is to develop 
a fully engineered translation system which can accommodate a wide range of monomers 
for applications in synthetic polymer synthesis.  
We successfully introduced a new assay in the lab which allowed analysis of our 
EF-Tu variants with OTSs from collaborating labs. We initiated transfer of materials from 
collaborating labs. During and after transfer of materials, we initiated email chains and 
conference calls and introduced new lab members to collaborators as appropriate.  
 
Figure 6.1 Replicating published data expressing GFP with tRNA variants (in 
duplicate). Solutions diluted 1:8 (blue), 1:4 (red), 1:2 (green), or not diluted (purple). 
Using Gibson assembly, we synthesized the plasmids required to assay our EF-Tus 
with the Ellington’s OTSs. We also ordered materials and arranged to use equipment to 
assay components. Following synthesis of plasmids, we successfully replicated the 

































































for the microplate reader to accurately read the OD600, but we found not diluting the 
samples aligned best with the published data. Measurements were taken ten times and 
averaged for each well. Duplicate wells were assayed for each sample.  
We then moved on to assay our EF-Tus in conjunction with the Ellington lab’s 
engineered aaRSs and tRNAs. Initial results looked promising (Figure 6.2). However, low 
reproducibility obscured meaning.  
 
Figure 6.2 Translation of GFP (1 amber mutation) by six tRNA variants. Results in 
triplicate show translation with no added EF-Tu (blue) and EF-4A (red). 
We began trouble-shooting problems with data reproducibility and decided the 
origin of replication on the EF-Tu plasmids was not compatible with the plasmids from the 
Ellington lab. At this point, we trained and transferred this aspect of the project to a 


































CHAPTER 7. FUTURE DIRECTIONS  
One challenge associated with this project was the size of the libraries. All libraries 
were extremely small (i.e. under 20 variants). With libraries that small, it becomes 
debatable if it is, in fact, a library or if it is a collection of very specifically engineered 
protein variants. Setting diction aside, these libraries were so small even with a highly 
functional library there was still a somewhat low probability of observing any desired 
outcome. Even previously published data using the REAP method used a library nearly an 
order of magnitude larger (over 90 variants).56 The difference in library size tentatively 
suggests that a larger library or a different tactic might be necessary to identify a variant 
with the desired activity.  
A second challenge was developing a functional assay. Despite all our efforts, the 
in vitro assay consistently suffered from reliability and reproducibility. Regularly the 
control experiments would stop working and required weeks to months of expensive and 
time-consuming work to identify the problem. In vitro translation is well known to be a 
challenging technique to master. Additionally, the radioactive label was highly temperature 
sensitive and degraded rapidly. It also had alanine and valine contamination. Eventually, 
we found a thermostable radio-compound, but we learned to be more vigilant about 
independently evaluating an inherited protocol.  
The in vivo assay was also impractical due to the timescale. The assay took ten to 
fifteen days to run one assay. In addition, the amount of time required to monitor samples 
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greatly limited the number of experiments that could be run concurrently or even in 
parallel.  
Even if these assays had been functional, an extremely low-throughput assay is, in 
hind-sight, potentially problematic given the EF-Tu libraries. With such small libraries, the 
probability of finding a hit was lower (even with a highly functional library). An alternative 
would have been to work with a high-throughput library. In fact, once we started working 
in 96-well plates that could be read on a plate reader, we began to collect relevant data. A 
high-throughput assay would have also allowed us to expand the variables we worked with. 
For example, instead of expanding the protein library, we could have utilized a wider range 
of other translation components (aaRS, tRNAs, ribosomes, etc.) which, when working with 
an extremely limited number of variants, is another tactic to expand the data gathered and 
improve the probably of getting a hit.  
Another challenge with this project was that utility had to be proven; a higher bar 
than discovery-based research. This was a challenging goal to achieve since in order for 
results to be worthy of publication, we had to prove our library variants not only worked 
but were actually better than existing options. This is a much higher standard and much 
more difficult to achieve.  
In recent months, we have been learning about high-throughput strategies from 
other labs. Given the data generated, we anticipate a larger library would be critical for 
moving forward. Alanine scanning or site-saturation mutagenesis would both be viable 
methods. Additionally a suitably complementary high-throughput assay, such as 
fluorescence activated cell sorting (FACS), would be important to move forward.  
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The data herein, suggests that REAP can be successfully used to identify sites 
suitable for mutation. They also suggest a single mutation can expand EF-Tu substrate 
compatibility. To the best of our knowledge, a comprehensive site-directed analysis of EF-
Tu has not been performed. Given the results generated, we theorize that EF-Tu variants 
with single mutations might be more powerful than testing multiple mutations.  
We would recommend developing a larger EF-Tu library by both expanding the 
number of sites targeted and by expanding the number of amino acids incorporated as 
substitutions. We recommend using a site-saturation approach via an NNK codon to target 
sites identified by REAP and ultimately generate a large library of single mutants. We also 
recommend targeting sites farther from the target. Although proximity to the amino acid 
binding pocket is a common method to select residues for mutation in EF-Tu, we theorize 
that an important advantage to using REAP is the ability to identify amino acid residues 
that might not be typically selected for mutation. We would be interested to see if a certain 
amino acid can be identified as the best substitution for EF-Tu.  
Complementary to this aim, we would also recommend adopting FACS as a high-
throughput screening technique. Using sfGFP as a reporter gene with either 1 or 3 amber 
mutations would permit much larger throughput than in vitro or in vivo assays.  
Tentatively, we would recommend using a two plasmid system. One plasmid would 
contain the EF-Tu variant and sfGFP. Another plasmid would contain aaRS:tRNA pairs. 
We would expect to originally screen using a sfGFP with three amber mutations since 
published data suggests an engineered EF-Tu might be more influential for multi-site ncAA 
incorporation. We would recommend building the cassettes from scratch rather than using 
purchased systems because we think it would permit greater control over promoter 
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selection. A challenge to this plan is that we might need a second fluorophore (mCherry, 
perhaps) that would allow us to normalize fluorescence to the number of plasmids 
expressing sfGFP in the cell. Both mCherry and sfGFP are fast maturing fluorophores 
which would benefit the system. There are obvious details to consider, for example sfGFP 
has a rather broad emission peak which overlaps with mCherry’s excitation spectrum; 
however, this pair is not uncommon to use jointly and we expect it would be suitable.  
Alternatively, an alanine-scanning approach could be used to identify relevant sites 
for mutation. While it has drawbacks, alanine scanning has been used to elucidate the role 
of amino acid residues in many proteins. To the best of our knowledge, this has not been 
attempted with EF-Tu which would put this in the category, perhaps, of fundamental 
protein research, thus having a lower bar to publication.  
The great challenge of working with EF-Tu is that results are predicated on the 
ncAA used. It is challenging to make sweeping statements about a helpmate protein. This 
is another reason why a high-throughput assay in which EF-Tu variants could be compared 
again many ncAAs would be tremendously useful.  
An alternative option would be to use post-translational modifications to detect 
amino acid incorporation. One of the challenges of assaying EF-Tu is the need to assay for 
broad incorporation. One way to do this would be to specifically incorporate ncAAs that 
can be acted upon post-translationally. Then, instead of detecting incorporation of the 
ncAA, you could detect the modified protein. You may even be able to detect incorporation 
of different substrates if they were acted upon differently post-translationally. A related 
strategy would be to use orthogonal tRNAs and orthogonal aaRSs that are known to be 
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polyspecific. By using polyspecific tRNAs and aaRS, we may generate more data and see 
a larger number of substrates be incorporated at that specific location.  
Alternatively, as a completely different approach it could be interesting to modify 
SelB for expanded substrate capacity. The advantage of this tactic is that SelB recognizes 
tRNAs that contain an additional nucleotide base pair in the acceptor stem. A modified 
SelB might be to exclusively recognize a specific subset of tRNAs that contain an extra 
nucleotide in the acceptor stem. This strategy might allow close control over which 
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